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Epigenetics of TET2 Loss in Myelodysplastic Syndromes 
 
Abstract 
 Myelodysplastic syndromes (MDS) are a class of myeloid malignancy 
characterized by peripheral blood cytopenias and impaired hematopoietic differentiation. 
Our understanding of the molecular basis of MDS has improved enormously in recent 
years due to clinical research efforts to characterize the spectrum of acquired mutations 
found in patients. This work has revealed that mutations in TET2 are common lesions in 
MDS and other myeloid malignancies. TET2 function has only recently been elucidated: 
TET proteins convert 5’-methylcytosine (mC) first to 5’-hydroxymethylcytosine (hmC), 
apparently the first step in an active DNA demethylation program that leads to the 
replacement of 5-mC with unmodified cytosine. My thesis work focuses on a 
characterization of TET2 loss on DNA methylation, and on how TET2 mutations impact 
patient response to treatment with hypomethylating agents.  
 
 We examined DNA methylation in a matched set of TET2-WT and -mutant MDS 
samples, and found that loss of TET2 results in global hypermethylation. This global 
increase is due to gains in intragenic methylation, specifically localized to intron-exon 
boundaries. We then used clonal TF1 cell lines with CRISPR/Cas9-engineered TET2 
mutations to examine global DNA hydroxymethylation. Loss of TET2 results in a global 
loss of 5-hmC. By aligning our methylation data with hydroxymethylation data from 
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TET2-WT cells, we were able to identify direct TET2 targets. Because changes in 
mC/hmC with loss of TET2 appeared to localize to intron-exon boundaries, we 
investigated the effect of aberrant methylation on mRNA splicing in our TF1 cell system. 
TET2 loss resulted in an overall increase in exon skipping, consistent with published data 
on the effect of methylation on splicing, and hypermethylated regions were enriched for 
alternate splicing events. These findings suggest that the alterations in hematopoietic 
differentiation seen in TET2-mutant models are due to shifts in the expression of different 
mRNA isoforms rather than wholesale changes in gene expression. Our data show that 
loss of TET2 function results in region-specific gains in DNA methylation, and that these 
alterations affect mRNA splicing by promoting exon skipping. Finally, we have found 
that presence of TET2 mutations are positively associated with response to HMA therapy. 
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Chapter 1 
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Introduction   
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Myelodysplastic Syndromes 
 
 Myelodysplastic syndromes (MDS) are a fairly broad category of myeloid 
malignancy, or disease of the myeloid lineage of hematopoiesis. In this section, I will 
discuss hematopoietic differentiation and how it is altered in MDS, clinical characteristics 
of MDS subtypes and current treatment options, as well as our current understanding of 
the genetics and molecular mechanisms underlying this disease. 
 
Normal Hematopoiesis 
 The hematopoietic system is a highly regenerative organ comprised of all mature 
blood cells and their immature precursors. These cells can be divided into two broad 
lineages: the lymphoid lineage, which is crucial for adaptive immune response, and the 
myeloid lineage, which is comprised of cells involved in innate immune response, 
oxygen delivery, and clotting. All of these cells are derived from a multipotent 
hematopoietic stem cell (HSC), a rare, usually quiescent cell that resides primarily in the 
bone marrow (Figure 1.1). The HSC is capable of both symmetric and asymmetric 
division, which allows for both differentiation and maintenance of the HSC pool. HSCs 
differentiate into multipotent progenitor (MPP) cells capable of reconstituting all 
hematopoietic lineages but not self-renewal. This cell population gives rise to more 
lineage-restricted progenitors: the common lymphoid progenitor (CLP) gives rise to cells 
of the lymphoid lineage but also has some potential to generate cells of the 
granulocytic/monocytic lineage (Adolfsson et al., 2005), while the common myeloid 
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progenitor (CMP) gives rise to the granulocyte-monocyte progenitor (GMP) and myelo-
erythroid progenitor (MEP). 
 
Figure 1.1: The hematopoietic hierarchy. 
This simplified diagram shows our current understanding of the hierarchy of 
hematopoietsis. All hematopoietic cells are derived from a bipotential LT-HSC, which 
can functionally sustain hematopoiesis over the lifetime of an organism. LT-HSCs give 
rise to a population of ST-HSCs capable self-renewal as well as generation of all 
hematopoietic lineages over a short-term period. More differentiated cells are incapable 
of self-renewal. 
 
 Our understanding of hematopoiesis is based on over a century of observation and 
experimentation. Although the observation that the hematopoietic system is organized as 
a hierarchy was made in the early 20th century (Maximow, 1909), the first evidence 
suggesting that a single cell might be capable of regenerating all hematopoietic cells 
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came in the middle of the 20th century, based on efforts to rescue bone marrow failure 
following exposure to radiation (Lorenz et al., 1951). Our current understanding of the 
hematopoietic stem cell and hierarchy is based largely on extensive in vivo 
transplantations in mice, which remain the gold standard model to define hematopoietic 
stem and progenitor cell potential. These experiments led to phenotypic definitions of 
populations enriched for hematopoietic stem cell potential, including LSK HSPCs and the 
current model for enrichment of LT-HSCs using SLAM family markers (Kiel et al., 
2005; Yilmaz et al., 2006). Our understanding of human hematopoietic biology was 
initially limited by technological considerations. The development of 
immunocompromised mouse models allowing xenotransplantation of human cells has 
allowed strides to be made in the phenotypic and molecular definitions of human 
hematopoietic stem and progenitor cells. (Iwasaki and Akashi, 2007) 
 Phenotypic definitions of hematopoietic stem and progenitor cells have been 
incredibly useful, but can be limiting in the context of disease and may not fully reflect 
real biological distinctions between stages of differentiation. Recent work examining 
transcriptional and epigenetic changes at multiple stages across the hematopoietic 
lineages has allowed us to gain a deeper understanding of the mechanisms that regulate 
self-renewal and differentiation. Initial studies in human hematopoietic cells have begun 
to describe the transcriptional networks regulating hematopoietic differentiation 
(Novershtern et al., 2011).  
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Hematopoiesis in MDS 
 MDS, broadly, are diseases marked by a block in differentiation and a loss of the 
ability of hematopoietic precursors to form functional mature hematopoietic cells. This 
results in a hypercellular bone marrow and in peripheral blood cytopenias. Recent work 
using clinical samples has demonstrated that the HSC is the disease-propagating cell in 
MDS, and the cell in which initial lesions leading to the development disease are 
acquired (Woll et al., 2014). These “MDS stem cells” have reduced functional capacity as 
measured by in vitro colony-forming assays, and give rise to dysplastic progenitor cells 
(Will et al., 2012). Will et al. further demonstrated that the expansion of progenitor cells 
seen in MDS correlates with disease subtype: low-risk subtypes tended to have an 
expanded population of the more primitive CMP, while high-risk subtypes showed 
expansion in the GMP population. MDS progenitors are capable of differentiation to 
phenotypically mature hematopoietic cells, but these cells are dysfunctional and exhibit 
increased levels of apoptosis (Albitar et al., 2002). 
 
Clinical Characteristics of MDS 
 MDS typically (though not exclusively) affects older individuals, with a median 
age of approximately 70 years (Aul et al., 1998; Rollison et al., 2008). Patients often 
present with fatigue, anemia, and recurrent infections due to impaired immune function 
(Hofmann and Koeffler, 2005). 
MDS is a highly clinically heterogeneous disorder, and includes multiple subtypes. 
These are classified based on morphology, and include refractory anemia (RA), 
refractory anemia with ringed sideroblasts (RARS), and refractory anemia with excess 
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blasts (RAEB). RA is marked by anemia and a low percentage of blasts (<1% in the 
peripheral blood, <5% in the bone marrow) and dysplasia in a single myeloid lineage. 
RARS is similar to RA, but is marked by presence of ringed sideroblasts and dysplasia in 
the erythroid lineage. RAEB is generally characterized by a higher percentage of blasts 
(1-19% in the peripheral blood, 5-19% in the bone marrow), as well as dysplasia in one 
or more myeloid lineages. A further class of myeloid malignancies has predominantly 
myelodysplastic features with some myeloproliferative characteristics; these are 
frequently classified as chronic myelomonocytic leukemia (CMML). Finally, MDS can 
be classified according to the presence of cytogenetic abnormalities. Unlike AML, where 
chromosomal translocations are more common, deletions and duplications predominate in 
MDS. The most common of these abnormal karyotypes are deletions within the q arms of 
chromosome 5 (del[5q]) or 20, loss of chromosome 7, and duplication of chromosome 8. 
(Adès et al., 2014)  
The majority of MDS cases arise with no known cause, though a small fraction 
are secondary to exposure to chemotherapeutic agents or environmental factors (Adès et 
al., 2014). Progression from MDS to AML occurs in a substantive fraction of patients, 
and despite biological differences the two diseases exist on a phenotypic spectrum. The 
exact mechanism of this transformation remains unclear, though silencing of critical 
tumor suppressor genes by aberrant DNA methylation has been suggested as a 
contributing factor (Jiang et al., 2009). Current WHO diagnostic standards differentiate 
MDS from AML by the percentage of immature cells (blasts) in the bone marrow: MDS 
is defined as <20% blasts, whereas a blast percentage greater than 20% is defined as 
AML (Albitar et al., 2002; Swerdllow et al., 2008). 
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MDS Therapies 
 Currently the only curative treatment for MDS is allogeneic bone marrow 
transplantation. However, given the high median age of the MDS patient and potential for 
complications from this procedure, many patients are instead placed on maintenance 
therapy to ameliorate symptoms and minimize disease burden (Stone, 2009). Patients 
with del(5q) respond well to treatment with lenalidomide, a thalidomide derivative that 
our laboratory has recently shown functions by inducing degradation of Casein Kinase 
1a1, which resides on the commonly deleted region of chromosome 5, thereby selectively 
targeting the del(5q) clone (Sekeres, 2011; Kroenke et al., in revision, 2015). Because 
alterations in methylation are common in MDS and associated with poor prognosis (Jiang 
et al., 2009), another option is therapy with the hypomethylating agents (HMAs) 
azacitidine or decitabine. These drugs induce widespread, non-specific demethylation via 
DNA methyltransferase inhibition, and improve survival and minimize progression to 
AML in responsive patients (Garcia-Manero and Fenaux, 2011). 
 
Molecular Basis of MDS 
MDS is less well understood at a molecular level than other myeloid 
malignancies; a quarter of patients have overt chromosomal abnormalities, but until 
recently the specific genes involved in disease initiation or progression were largely 
unknown. A notable exception was the subset of MDS patients with del(5q), in which one 
of the critical deleted genes, RPS14, has been shown to play an important role in 
erythroid development (Ebert et al., 2008). More recently, a number of large-scale 
sequencing projects have deepened our understanding of the mutational spectrum in 
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MDS, and have revealed that the most frequently mutated classes of genes in this disease 
are involved in mRNA splicing and epigenetic modifications (Table 1.1). Approximately 
half of all MDS patients have somatic mutations in a spliceosome component, including 
SF3B1, U2AF1, SRSF2, and ZRSR2, all of which are involved in recognition of the 3’ 
splice site. These mutations tend to be mutually exclusive with other splicing factor 
mutations, and are typically missense mutations resulting in gains of function. (Pellagatti 
and Boultwood, 2015)  
Table 1.1: Common somatic mutations and their frequencies in MDS (Pellagatti and 
Boultwood, 2015) 
 
Gene Frequency in MDS 
DNA/chromatin modifiers   
TET2 20-25% 
IDH1/2 5% 
DNMT3A 10% 
ASXL1 10-15% 
EZH2 5% 
    
Splicing factors   
SF3B1 20-28% 
SRSF2 12-15% 
U2AF1 7-9% 
ZRSR2 3-11% 
    
Other   
RUNX1 10% 
TP53 5-10% 
JAK2 5% 
NRAS 5% 
KRAS 2% 
ETV6 2-5% 
EVI1 1-2% 
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Somatic mutations in Ten-Eleven Translocation 2 (TET2), found in 20-25% of 
patients, are among the most common lesions in MDS, and are also frequently found in 
other myeloid malignancies including AML. In contrast to mutations in spliceosome 
components or in members of tyrosine kinase pathways, which are functionally redundant 
and therefore rarely co-occur in the same patient, TET2 mutations can be found in 
combination with nearly every other known mutation in MDS. This implies a novel 
functional role for TET2 loss in the development and progression of MDS. The sole 
exceptions are gain of function mutations in IDH1/2, which are rarely found co-mutated 
with TET2 mutations. IDH1/2 mutations are neomorphic, resulting in the production of 
the oncometabolite 2-hydroxyglutarate (2-HG) which inhibits the function of 2-
oxoglutarate-dependent proteins, including TET family members (Figueroa et al., 2010).  
 
TET2 in MDS 
 
 As discussed above, somatic mutations in TET2 are a frequent event in MDS. 
TET2, like other TET family members, converts methylcytosine to 
hydroxymethylcytosine. The role of loss of this function on MDS development and 
progression remains unclear. In this section I will discuss the role of Tet2 in 
hematopoiesis, the function of TET family proteins, and the importance of DNA 
methylation in hematopoiesis. 
 
 
 
!! 10!
TET2 in Hematopoiesis and Hematologic Malignancy 
 Until recently, of the TET family members, only TET1 had been implicated in 
myeloid malignancies, as a fusion partner of MLL in some patients with AML (Lorsbach 
et al., 2003). In the past several years, however, a number of groups have reported TET2 
loss-of-function mutations in primary patient samples of MPN, MDS, CMML, and AML 
(Abdel-Wahab et al., 2009; Couronné et al., 2010; Delhommeau et al., 2009; Jankowska 
et al., 2009; Langemeijer et al., 2009; Saint-Martin et al., 2009; Tefferi et al., 2009a; 
2009b). In these studies TET2 has been found to be mutated in CD34+ HSPCs. Studies 
from our own laboratory have confirmed these findings, and have demonstrated that 
TET2 mutations coincide with mutations in a number of other common tumor suppressor 
mutations in MDS, indicating that TET2 mutations are likely to affect a non-redundant 
functional pathway in MDS pathogenesis (Bejar et al., 2011). A recent study reports that 
acquisition of TET2 mutations is associated with leukemic transformation in MPN 
patients who subsequently develop secondary AML (Abdel-Wahab et al., 2010).  
 Studies in patient samples have been limited by availability and technological 
constraints. Development of a Tet2 conditional knockout mouse has been critical to a 
dissection of TET2 function in hematopoiesis. Multiple models of conditional deletion of 
Tet2 in hematopoietic cells have been developed, and show that loss of Tet2 results in an 
increase in self-renewal in the HSC compartment, an expansion of the GMP population 
and corresponding expansion of the granulocyte/monocyte populations, and the 
development of an MDS- or CMML-like disease (Moran-Crusio et al., 2011; Quivoron et 
al., 2011). Taken together, these data suggest that loss of TET2 may affect the self-
renewal and differentiation pathways of hematopoietic cells.   
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Function of TET Family Members 
 TET2 belongs to a family of three 2-oxoglutarate and Fe(II)-dependent 
dioxygenases, and is expressed in many tissues, including the bone marrow, 
hematopoietic stem/progenitor cells (HSPCs), and peripheral blood (Bocker et al., 2012; 
Langemeijer et al., 2009). Tahiliani et al. initially demonstrated that the TET family 
member TET1 converts 5-methylcytosine to 5-hydroxymethylcytosine (hmC) (Tahiliani 
et al., 2009). The precise function of 5-hmC is unknown, and will be discussed further 
below, but it is hypothesized to be a DNA-demethylation signal (Mullighan, 2009). 
Given our current understanding of the function of DNA methylation, this suggests that 
TET family members may play an important role in the regulation of gene transcription. 
The oxygenase domains in TET1 that are predicted to catalyze the transfer of a hydroxyl 
group are conserved in TET2 and TET3, and recent studies have confirmed conservation 
of this function in murine Tet2 (Ito et al., 2010). Although no data have been published 
on the direct function of human TET2, the study of TET1 and the high level of 
conservation between functional domains of TET/Tet family members support the 
hypothesis that methylcytosine dioxygenase function is also conserved among all TET 
family members. Furthermore, myelodysplastic syndrome (MDS) and myeloproliferative 
neoplasm (MPN) patient samples with TET2 mutations were shown to have lower levels 
of global hmC than healthy controls or patients without TET2 mutations (Jiang et al., 
2009).  
 Two groups have further characterized the function of TET proteins by describing 
processive reactions in which 5-hmC is converted first to 5-formyl-cytosine (5-fC) and 
then to 5-carboxyl-cytosine (5-caC) by TET proteins (He et al., 2011; Ito et al., 2010). 
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These latter two modifications appear to be recognized by the base excision repair (BER) 
pathway member thymine-DNA glycosylase (TDG), leading to their removal and 
replacement with unmodified cytosine (He et al., 2011). These findings provide a model 
for active demethylation of DNA, initiated by TET proteins. Whether or not 5-hmC is a 
transient mark in vivo is controversial: it is unclear whether 5-hmC has a functional role 
separate from its role as an intermediate in the demethylation process. Interestingly, 
several methylcytosine binding domain (MBD) proteins may preferentially recognize 5-
hmC, while others can bind both 5-mC and 5-hmC, suggesting that 5-hmC may be used 
to fine-tune the response to DNA modifications (Mellen et al., 2012; Scourzic et al., 
2015; Yildirim et al., 2011).  
 
DNA methylation and hematopoiesis 
 DNA methylation is a means of epigenetic regulation that is increasingly being 
recognized as critical for the proper specification and differentiation of many tissues, 
including hematopoietic cells. For the purposes of this thesis, methylated DNA refers 
specifically to the methylation of the base cytosine, typically found next to a guanine and 
known as a CpG dinucleotide. Non-CpG methylation, referring to modification of a 
cytosine adjacent to a base other than guanine, is less well understood (Guo et al., 2013).  
 Patterns of DNA methylation are set up during embryogenesis by DNA 
methyltransferase (DNMT) 3a and DNMT3b, which are capable of methylating cytosine 
de novo (Hsieh, 2000). Methylation is lost as DNA replicates at each cell division, and 
must be maintained by DNMT1, which has higher affinity for hemimethylated DNA 
(Bashtrykov et al., 2012). DNA methylation must therefore be actively maintained, and 
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can be lost passively through a decrease in DNMT1 activity. The existence of an active 
DNA demethylation program in mammals has been postulated for many years, but most 
putative mammalian demethylase mechanisms have either been disproven or never 
replicated (Ooi and Bestor, 2008). More recent work implicating the TET family proteins 
in DNA demethylation will be discussed below.  
 The regulation of DNA methylation is critical to understand because of the 
importance of this modification in the regulation of transcription and therefore cell state. 
DNA methylation is typically found concentrated in CpG rich regions called CpG islands 
(CGI) and at gene promoters, though more recent work has explored the importance of 
methylation outside these areas, in regions called CGI shores (within 2kb of a CGI) or 
shelves (2kb upstream or downstream of CGI shores) (Álvarez-Errico et al., 2015), as 
well as in gene bodies. Nevertheless, CGI and promoter methylation remains the best 
understood in terms of function: heavily methylated CGI and promoters are associated 
with repression of transcription of the associated gene. Transcriptional repression through 
methylation is achieved in two ways. First, methylcytosine can directly inhibit binding of 
transcription factors and other DNA-binding proteins. Second, methylcytosine can be 
bound by various methyl-binding domain (MBD) proteins, which in turn act as inhibitors 
of transcription. (Schübeler, 2015)  
 Methylcytosine-mediated gene silencing is important during development, but 
also in the differentiation of mature cells from precursors. Methylation dynamics during 
hematopoiesis have been well studied in the mouse, and reveal that methylation patterns 
of HSCs are more closely related to myeloid lineage cells than to lymphoid lineage cells, 
implying that HSCs have some inherent myeloid bias (Beerman et al., 2013). Methylation 
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overall increases as HSCs differentiate, with homeobox genes in particular becoming 
repressed through increased methylation (Bock et al., 2012). In myeloid lineage cells, 
however, changes in methylation are more dynamic. Although DNA methylation 
increases initially in the transition from HSC to CMP, terminally differentiated myeloid 
cells are typically hypomethylated relative to HSCs (Álvarez-Errico et al., 2015). Loss of 
maintenance methylation in HSCs in a conditional Dnmt1 knockout mouse diminishes 
self-renewal and engraftment capacity as well as specifically myeloid lineage 
differentiation, highlighting the functional importance of DNA methylation in 
hematopoiesis (Trowbridge et al., 2009) 
 
Summary/Rationale 
 
 Loss of TET2 is a frequent event in myeloid malignancies, including MDS, and 
evidence from murine models suggests that Tet2 deficiency affects HSC function and 
functional capacity. Lesions in TET1 or TET3 are comparatively rare in hematopoietic 
malignancies (Abdel-Wahab et al., 2009; Atak et al., 2012; Lorsbach et al., 2003). This 
may be due to tissue specificity of the TET family members, but also points to a unique 
role for TET2 in hematopoiesis and myelopoiesis. 
 Given the known function of TET family members as methylcytosine 
dioxygenases, a logical hypothesis follows that loss of TET2 function would lead to 
global and/or site-specific DNA hypermethylation. Results from initial studies on the 
effect of TET2 loss on DNA methylation have been mixed, however, possibly due to 
methodology or confounding factors affecting methylation status (Figueroa et al., 2010; 
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Ko et al., 2010). Furthermore, no group has examined changes in hydroxymethylation 
relative to changes in methylation, or the functional effects these epigenetic changes may 
have in hematopoietic cells. For these reasons, I aimed to carefully assess whether and 
how DNA methylation changes with loss of TET2 in primary MDS samples, as well as in 
genetically engineered model systems, and to link any changes in methylation to 
hydroxymethylation and other functional changes. Finally, given our hypothesis 
regarding the effect of TET2-loss on DNA methylation, we sought to determine whether 
the presence of TET2 mutations might affect response to HMAs.  
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Chapter 2 
_____________________________________________________________ 
Materials & Methods  
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MDS patient samples 
Bone marrow aspirate mononuclear cells from MDS patients were obtained as 
described (Bejar et al., 2011). Patients provided written informed consent according to 
protocols developed by the institutional review board at the institution collecting the 
samples. Genomic DNA was stored at the Biological Samples Platform at the Broad 
Institute in Cambridge, MA.  
 
CD34+ Cell Experiments 
Isolation 
Mononuclear cells were isolated from human umbilical cord blood (National Cord 
Blood Program, NYBC)) by density gradient centrifugation with Ficoll-Paque. CD34+ 
stem/progenitor cells were isolated from total mononuclear cells using anti-CD34 
antibody and the autoMACS Pro Separator (Miltenyi).  
Culture Conditions  
 hUBC-derived CD34+ cells were cultured in StemSpanTM SFEM (Stemcell 
Technologies) with Penicillin/Streptomycin (100 U/mL), glutamine (2 mM), lipids (40 
µg/mL), TPO (50 ng/mL), SCF (25 ng/mL), and FLT-3 (40 ng/mL) (FST media).  
shRNA Knockdown 
 Lentivirus was produced according to standard protocols from pLKO containing 
shRNA against TET2 (TRC 122172: GCGTTTATCCAGAATTAGCAA; TRC 144344: 
CCTTATAGTCAGACCATGAAA) or nontargeting control shRNA, and concentrated 
via ultracentrifugation. Thawed hUBC-derived CD34+ cells were plated in 48-well 
format 24 hours post-thaw in 100 µL FST media with 2x cytokines and polybrene (8 
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µg/mL), and mixed with 100 µL concentrated virus. Plates were spun at 1500RPM for 60 
minutes at 23°C, then incubated at 37°C for 1 hour, after which 200 µL FST media was 
added and cells were cultured overnight. Antibiotic selection was performed for 3 days 
with puromycin (2 µg/mL).  
 
TF1 cells 
TF1 erythroleukemia cells were grown in RPMI supplemented with 10% FBS, 
1% Penicillin/Streptomycin, and GM-CSF (2ng/mL). To generate TET2-mutant TF1 cells, 
we transduced cultures with a single lentiviral vector containing a puromycin selection 
marker, Cas9 and a guide RNA targeting either TET2 exon 3 (Supplemental Figure 4) or 
GFP (control) as described (Sanjana et al., 2014). Cells were placed under puromycin 
selection 24 hours after infection, and grown under selection for one week. Single cells 
were then sorted into 96-well plates and single cell clones were expanded for three weeks. 
Genomic DNA from clonal lines was extracted and sequenced using primers surrounding 
the gRNA target sequence.  
 
Methylation profiling and analysis 
RRBS was performed as described (Gu et al., 2010; Meissner, 2005). Global 
methylation was determined by averaging relative methylation across 1kb tiles for all 
well-covered (≥10 reads) regions. Regional methylation was determined in the same way, 
with the following changes: promoters were defined as the 2kb region centered at the 
transcription start sites of Refseq genes, CGIs were defined using a biologically-verified 
set (Illingworth et al., 2010), enhancers were defined as H3K27ac peaks in CD34+ cells 
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from Roadmap samples (GSM 772885, GSM772870, GSM772894) or Vista dataset, 
intron-exon regions were defined as the 1kb region centered at non-promoter intron-exon 
junctions of RefSeq genes. WGBS was performed as described (Gifford et al., 2013). 
 
RNA Sequencing 
Total RNA was extracted from 4 MDS samples stored in GITC buffer in an 
RNAse-free environment using standard protocols, and the product of RNA extraction 
was cleaned up using the PrepEase RNA Spin kit (Affymetrix). Total RNA from TF1 cell 
lines was extracted using the PrepEase RNA Spin Kit. RNA sequencing was performed 
on all samples using the Illumina TruSeq platform to a depth of ≥50M strand-specific 
paired reads. Reads were aligned to the reference genome using the Picard pipeline. 
Whole transcriptome analysis was performed using Cufflinks, and quantification of 
alternate splicing events was performed using JuncBASE. 
 
MeDIP PCR 
Genomic DNA from TF1 cell lines was extracted (Qiagen Blood Mini) and 
digested with MseI according to standard protocols. MeDIP was performed in triplicate 
for each cell line using the MethylCollector Ultra kit (Active Motif) according to the 
manufacturer’s protocols. Primers for individual DMRs were designed to fall within 5’ 
and 3’ MseI cut sites most proximal to each DMR. Quantitative PCR was performed 
using the products of MeDIP and DMR-specific primers, and products measured with 
SYBR-Green. Each reaction was performed in triplicate, and was normalized to input 
DNA to obtain a final value for total methylation at each DMR. 
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5-hmC detection 
Dotblots 
Genomic DNA from TF1 cell lines (TET2-wildtype or –deficient) was extracted 
(Qiagen Blood Mini) and digested with MseI according to standard protocols. 
Fragmented DNA (400ng/sample) was denatured (NaOH final concentration 0.1M, 95C, 
5’) and then cooled on ice with the addition of ammonium acetate (0.66M final 
concentration). The dotblot apparatus (Bio-Rad 170-6545) was assembled and samples 
were loaded and transferred to a rehydrated nitrocellulose membrane according to 
manufacturer instructions. Samples were crosslinked to the membrane (UV Stratalinker, 
Stratagene), which was blocked overnight (10% milk, 1% BSA in PBS + 0.1% Tween). 
The membrane was incubated with primary antibody to 5-hmC (Diagenode C15220001, 
1:500) and an HRP conjugated secondary antibody (Santa Cruz Biotech sc-2032) with 
standard washes. 
hmC Sequencing (RRHP) Library Preparation 
Genomic DNA was extracted from TF1 cell lines as described above. Genomic 
DNA was fragmented overnight at 37°C with a hydroxymethyl-insensitive enzyme, MspI, 
and purified using the DNA Clean and Concentrator kit (Zymo Research). Modified 
Illumina TruSeq P5 and P7 adapters containing 5’-CG overhangs were ligated onto the 
digested DNA using T4 DNA ligase (2 hours at 16°C). Libraries were then strand 
extended at 72°C with Taq DNA Polymerase. The adapters were designed to regenerate 
the 5’-CCGG site at the P5 junction while the P7 adapter generates a 5’-TCGG junction, 
making it insensitive to MspI digestion. Adapterized libraries were treated with β- 
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glucosyltransferase to label 5-hmC modifications and purified using the DNA Clean and 
Concentrator kit. The glucosylated libraries were then subjected to an overnight MspI 
digestion at 37°C, cutting any fragments not containing a glucosyl-5hmC site at the P5 
CCGG junction. After incubation, the libraries were size-selected from 100bp to 500bp 
and purified using the ZymoClean Gel DNA Recovery Kit (Zymo Research). The 
fragments were amplified using OneTaq 2X Master Mix (NEB), and the PCR conditions 
include an initial denaturation of 94°C for 30 sec followed by 12 cycles of 94°C for 30 
sec, 58°C for 30 sec, and 68°C for 1 min. Fragments containing 5-hmC were positively 
selected during PCR amplification with adapter-specific indexing primers whereas 
fragments lacking glucosylated-5-hmC at the P5 junction were cleaved and, therefore, not 
amplified by PCR. Amplified libraries were purified using the DNA Clean and 
Concentrator kit, and multiplexed using equal volume of the libraries. All adapters and 
primers used were synthesized by Integrated DNA Technologies. 
Bioinformatics processing and statistical analyses 
Sequence reads from RRHP libraries were first processed to trim off the low 
quality bases and the P7CG adapter at the 3’ end of the reads. Reads were then aligned to 
the reference genome using the Bowtie default parameters and --best. Aligned reads with 
the MspI tag (CCGG) were counted. The correlation analysis between different RRHP 
libraries was performed by comparing the presence of the tagged reads at each profiled 
MspI site, and Pearson’s coefficient was calculated accordingly. 
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Patient Samples and Hypomethylating Agent Response Assessment 
A total of 213 MDS patients treated with azacitidine or decitabine were included 
in this study. Samples were obtained from patients treated at the Dana-Farber Cancer 
Institute (2003-2010, n = 42), the MD Anderson Cancer Center (2003-2010, n = 104), 
and as part of the DACO-020 (ADOPT) clinical trial of decitabine (2005-2006, n = 67). 
All samples were collected with patient consent under IRB-approved protocols in 
accordance with the Declaration of Helsinki. Response to treatment was assessed using 
International Working Group (IWG) response criteria revised in 2006. Patients with 
either a complete response (CR), partial response (PR), or hematologic improvement (HI) 
were considered as ‘responders’ (R, n = 100, 47%). whereas patients described as having 
‘no response’, ‘stable disease’, ‘progressive disease’, ‘death’ before response assessment, 
or ‘not evaluable’ were considered ‘non-responders’ (NR, n = 113, 53%). 
 
Sample Processing, DNA Sequencing, and Mutation Analysis  
DNA was extracted from bone marrow mononuclear cells or peripheral blood 
samples collected prior to treatment (median 18 days, range 9 to 119). Whole genome 
amplification of DNA for each sample was performed using the REPLI-g kit from 
Qiagen. A genotype fingerprint of 22 common single nucleotide polymorphisms (SNP) 
for each sample was generated by MALDI-TOF genotyping (Sequenom). Target regions 
of 40 genes (Supplemental Table 4.1) and genotype fingerprint regions were enriched 
using Agilent SureSelect hybrid capture system according to manufacturer instructions. 
Barcoded samples were pooled in equimolar amounts and subjected to 100 nucleotide 
paired-end sequencing on an Illumina Hi Seq 2000. Sequence reads were aligned to the 
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human genome (Build 37) using the Burroughs-Wheeler algorithm (Li and Durbin, 2010). 
The Genome Analysis Toolkit was used to clean and locally realign reads prior to calling 
missense and insertion/deletion variants using MuTect (Cibulskis et al., 2013; DePristo et 
al., 2011). Sample identity was confirmed by matching fingerprint genotype calls. 
Synonymous variants, non-coding variants more than 6 bases from splice junctions, or 
variants present in databases of “normal” genomes (dbSNP 132 or NHLBI Exome 
Sequencing Project) at a population frequency of 1% or more were discarded. Remaining 
variants were considered candidate somatic mutations. 
 
Competitive Murine Bone Marrow Transplants  
Age-matched Tet2fl/fl; Mx-Cre+ and Tet2+/+; Mx-Cre+ donor animals (CD45.2) 
were treated with pIpC (15µg/g IP) for three non-consecutive days to induce excision of 
exon 3 of Tet2 (Moran-Crusio et al., 2011). Donor bone marrow was harvested two 
weeks post-pIpC and mixed in a 1:2 ratio with bone marrow harvested from 45.1 WT 
donors (B6.SJL-Ptprca Pepcb/BoyJ; Jackson), and was then transplanted into 45.1 
recipients for a total of 1 million cells/recipient. Peripheral blood engraftment was 
assessed by FACS at two weeks post-transplant, at which point recipient mice were 
divided into treatment groups (n=7 per group) and treated daily with either 5-azacitidine 
(AZA; 2.5mg/kg IP; Santa Cruz Biotechnology) or vehicle control on the following 
schedule: two weeks on, two weeks off. Peripheral blood chimerism and CBC were 
assessed following each round of treatment. 
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Statistical Methods  
Categorical variables were compared using a Fisher exact test or chi-square test as 
appropriate, while continuous variables were compared using a Wilcoxon rank-sum test. 
A Cochran-Mantel-Haenszel (CMH) test was used to test for differences in response rate 
by mutational status controlling for treatment. Unadjusted and adjusted logistic 
regression models were used to predict response to therapy. Models were adjusted for 
covariates including age (≥70 yrs. vs. <70 yrs.), sex, International Prognostic Scoring 
System (IPSS) risk group (low/intermediate 1 vs. intermediate 2/high) and treatment 
(azacitidine vs. decitabine alone vs. decitabine ± other). The odds ratio (OR) and 95% 
confidence intervals (CI) were estimated for the risk group (mutated) and compared to 
the reference group (wild-type).  The Hosmer and Lemeshow goodness-of-fit test was 
used to assess model fit of logistic regression models. Overall survival was calculated 
from the time of treatment to the time of death from any cause or was censored at the date 
last known alive and was compared using a log rank test. Unadjusted and adjusted 
univariate Cox models were also constructed using with the same covariates. For the 
competitive murine experiments, the percent 45.2 chimerism was calculated for each time 
point. Error bars indicate standard error of the mean (SEM) for each group, and p-values 
for each time point were calculated using a two-sample t-test. All p-values reported are 
two-sided and considered significant at the 0.05 level. No adjustments were made for 
multiple hypothesis testing. 
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Chapter 3: Results – Part 1 
_____________________________________________________________ 
TET2 loss in myelodysplastic syndrome results in intragenic 
hypermethylation and increased exon skipping  
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Contributions 
 I selected patient samples for methylation profiling, and, in collaboration with 
others (see below), developed approaches for analysis of all genomic/transcriptomic data. 
I generated the TET2-null TF1 cell system used for hydroxymethylation profiling and 
RNA-sequencing, and performed all validation experiments for genomic/transcriptomic 
studies. I performed all in vitro hUBC-derived CD34+ cell and murine experiments. 
 MDS patient samples used in this work were first characterized by Rafael Bejar 
(Bejar et al., 2011), who also advised on sample selection. MDS samples were obtained 
from Azra Raza’s laboratory. All methylation profiling experiments were done in 
collaboration with members of Alex Meissner’s laboratory, notably Hongcang Gu, who 
performed the bisulfite conversion and sequencing, and Kendell Clement, with whom I 
worked closely to develop approaches to analyze the data generated and who performed 
all computational work. 5-hmC capture and sequencing for hydroxymethylation profiling 
(RRHP) was done at Zymo Research. RNA-sequencing was done through the Genomics 
Platform at the Broad Institute, and analysis of results was done in collaboration with 
Michael Burger and Aviad Tsherniak. Angela Brooks (Matthew Meyerson laboratory) 
provided invaluable advice about use of the JuncBASE analysis platform for alternate 
splicing events. Rebekka Schneider-Kramann, Ann Mullally, and Michelle Chen 
provided technical support for murine experiments. 
 
 
Note: We are currently preparing a manuscript for publication based on work presented 
in this chapter. 
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Summary 
 
The methylycytosine dioxygenase TET2 is among the most commonly mutated 
genes in myelodysplastic syndromes (MDS), but the genomic consequences of TET2 
mutation in myeloid transformation remain unclear. The effect of TET2 loss on DNA 
methylation in human patients is controversial. We examined the DNA methylation status 
of a well-characterized cohort of MDS patients (n=66) and found increased global 
methylation in TET2 mutant samples versus TET2-wildtype samples. We found no 
difference in methylation between groups at promoters or within enhancers, but TET2-
mutant samples had increased intragenic methylation, particularly at intron-exon 
boundaries. Furthermore, regions hypermethylated in TET2-deficient samples are 
enriched for hydroxymethylcytosine in TET2-WT cells. Analysis of RNA sequencing 
revealed an increase in exon-skipping events in TET2-null cells compared with WT, 
specifically involving regions of aberrant hypermethylation in TET2 mutant patients. Our 
data suggest that loss of TET2 results in aberrant hypermethylation at intron-exon 
boundaries, which in turn alters mRNA splicing. 
 
 
Introduction 
 
TET family members convert 5-methylcytosine to 5-hydroxymethylcytosine (Tahiliani et 
al., 2009), which is then thought to be further modified and replaced with unmodified 
cytosine via the base excision repair (BER) pathway (He et al., 2011; Ito et al., 2011). 
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TET2 and family members are therefore important regulators of DNA methylation. High 
levels of DNA methylation in CpG islands near promoters have long been associated 
with the repression of transcription (Klose and Bird, 2006). DNA methylation at 
enhancers has also been shown to repress transcription, and is dysregulated in cancer 
(Aran et al., 2013). Somatic mutations in TET2 leading to loss of methylcytosine 
dioxygenase function (Ko et al., 2010) are extremely common in a wide variety of 
myeloid malignancies, including myelodysplastic syndromes (MDS) and acute myeloid 
leukemia (AML), and are associated with acquired somatic mutations in spliceosome 
components such as ZRSR2 and SRSF2 (Haferlach et al., 2013; Hanssens et al., 2014; 
Papaemanuil et al., 2013).  
 
Previous studies examining the effect of TET2 loss on DNA methylation in 
myeloid malignancies have reached conflicting conclusions. Ko et al. investigated 
changes in methylation status with TET2 loss in a set of patients with varying myeloid 
malignancies (MDS, MPN, primary and secondary AML) and found overall 
hypomethylation of TET2-mutant samples when compared to TET2-WT samples (Ko et 
al., 2010). This study used the Illumina Infinium array to assess changes in methylation, 
which is hampered by limited genomic coverage (Bock et al., 2010). Figueroa et al. used 
the HELP assay to assess methylation and found that AML patients with TET2 mutations 
have increased methylation when compared to normal bone marrow (Figueroa et al., 
2010). The discrepancy in findings between these two studies may be due to the use of 
different assays to detect DNA methylation, the presence of confounding somatic 
mutations with the potential to affect DNA methylation, or the choice of controls.  
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Results 
 
 We sought to characterize the effects of somatic TET2 mutation on DNA 
methylation in a well-annotated set of samples from a single disease, MDS, by reduced-
representation bisulfite sequencing (RRBS). We analyzed genomic DNA isolated from 
bone marrow aspirates from 66 MDS cases matched for TET2 mutation status, somatic 
mutations in other genes, MDS subtype, blast counts, sex, and age (Table 3.1, 
Supplemental Table 3.1). Genome methylation analyses showed that MDS samples 
were highly methylated regardless of genotype (Supplemental Figure 3.1a), but we 
observed a shift towards increased global methylation in the TET2-mutant samples versus 
WT (Supplemental Figure 3.1b).  
 
Table 3.1: Somatic Mutations in and Clinical Characteristics of MDS Samples.  
 
Columns represent individual patients, while rows describe somatic mutations or patient 
characteristics. -5q: del(5q); Complex: ≥3 chromosomal aberrations. 
 
 
<60 60-69 70-79 
Male Female
<10 10-20 
-5q Complex
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In the bone marrow of MDS patients, the percentage of cells bearing TET2 
mutations vary, and these mutations can be either heterozygous or homozygous. To 
minimize the dilutive effects of cells without TET2 mutations, we performed a focused 
analysis of the 17 samples with a TET2 mutant allele fraction of >40% and matched 
samples without TET2 mutations (Bejar et al., 2011) (Supplemental Table 3.2a, 
Supplemental Figure 3.2). Consistent with the observed effects of TET2 mutations, we 
found that the samples with higher TET2 mutant allele fraction had a greater increase in 
methylation at regions of high overall methylation, providing further evidence that the 
observed shift in methylation is due to TET2 loss (Supplemental Figure 3.1c, d). We 
binned these results by relative methylation level to compare the number of regions with 
low, intermediate, and high methylation within the TET2 mutant and WT groups, and 
found that TET2-mutant samples had significantly increased frequency of regions with 
high levels of methylation (0.8-1.0) offset by a concomitant decrease in the frequency of 
regions with intermediate methylation (0.6-0.8) (Figure 3.1a). These results indicate that 
loss of TET2 leads to increased global methylation in a dose-dependent manner. 
We next sought to determine the genomic regions most affected by TET2 
mutation. To control for differences in region size we normalized differential methylation 
in each region to CpG content (Figure 3.1b). While the majority of total CpGs were 
located in promoters, CpG islands, and enhancers, these regions contained only a small 
fraction of differentially methylated CpGs, and differential methylation in these regions 
was evenly split between the TET2-mutant and TET2-WT samples (Supplemental Table 
3.3). Although promoters are enriched for 5-hmC, and Tet family binding in murine ES 
cells (Wu et al., 2011), we found no significant difference in methylation between groups 
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at promoters, which had low levels of methylation overall (Figure 3.1c, d). Methylation 
at enhancers has been implicated in regulation of transcriptional control (Aran et al., 
2013), but we saw no significant differences between TET2 mutant and WT groups in the 
overlap of our methylation data and two separate enhancer datasets (Supplemental 
Table 3.3). In contrast, non-promoter intron-exon boundaries showed marked enrichment 
for differential methylation despite containing a relatively low fraction of total CpGs 
(Figure 3.1e, f). 
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Figure 3.1: TET2 mutant MDS samples are hypermethylated vs WT.  
 
Well-covered CpGs were binned according to level of relative methylation and statistics 
were performed between TET2 mutant and TET2 WT groups for each bin (e; paired t-test, 
* indicates p<0.05) (a); Differential methylation was normalized to region size for the 
regions indicated, and was calculated as the fraction of differentially methylated CpGs in 
a given region relative to the fraction of total CpGs in that region (b); Promoter 
methylation (c,d) and intron-exon methylation (e, f) shown as comparison of average 
methylation between TET2 mutant and TET2 WT groups (c, e) and relative methylation 
of each group as a function of density (d, f); Differential methylation across the promoter 
region and the intron-exon region was averaged and plotted as a function of distance from 
the TSS and the 5’ and 3’ exon boundary, respectively. 
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Figure 3.1, continued 
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 One limitation of these analyses is that the MDS samples available to us were 
genomic DNA from whole bone marrow aspirates containing a heterogeneous mixture of 
cells. We therefore sought to confirm our previous findings in genetic models of 
TET2/Tet2 loss. We generated TET2-deficient hUBC-derived CD34+ HSPCs using an 
shRNA knockdown approach, and isolated LSK cells from pI:pC-treated Mx-Cre; Tet2fl/fl 
mice. The methylation status of genomic DNA from these cells and corresponding 
wildtype cells was analyzed by RRBS as before. Global methylation and intron-exon 
methylation were both increased in the TET2/Tet2-deficient cells versus wildtype, while 
promoter methylation was unchanged (Supplemental Figure 3.3). While these results 
did not reach statistical significance due to small sample size, the trends seen in 
methylation changes in genetic models of TET2 loss reinforce our previous findings in 
MDS samples. 
 
 The finding that intron-exon boundaries contained a high relative proportion of 
differential methylation in our samples is consistent with reports that intron-exon 
boundaries are enriched for 5-hmC in neuronal tissues (Khare et al., 2012). We examined 
the precise location of differential methylation relative to the intron-exon boundary by 
plotting the relative methylation level of well-covered differentially methylated CpGs 
within 100bp of an intron-exon boundary relative to distance the intron exon boundary. 
We saw no bias in differential methylation towards 5’ versus 3’ boundaries, but observed 
a consistent gain in methylation in the TET2 mutant group across this region, with a 
greater absolute number of DMRs in exons versus introns proximal to intron-exon 
junctions (Figure 3.1g).  
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 Methylation profiling by RRBS is designed to analyze CpG-rich regions, and 
although we obtained good coverage relative to RRBS standards, only 17% of intron-
exon junctions in the human genome were analyzed in our data (Supplemental Figure 
3.4). To examine TET2-dependent methylation at all intron-exon junctions, we 
performed whole-genome bisulfite sequencing (WGBS) on two MDS patient samples 
with TET2 mutations and two without TET2 mutations (Supplemental Table 3.4). 
WGBS results confirmed the RRBS results in all regions, demonstrating a significant 
gain of methylation in the TET2-mutant samples (Supplemental Figure 3.5a), but no 
differences in methylation at promoters (Supplemental Figure 3.5b). At intron-exon 
boundaries, we again observed an overall significant increase in methylation in TET2-
mutant samples (Figure 3.2a, b). WGBS results for specific regions were concordant 
with results obtained previously by RRBS, and showed expanded regions of differential 
methylation concordant with hmC content in TET2-wildtype cells (Figure 3.2d-g).  
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Figure 3.2: Intron-exon hypermethylated regions in TET2-mutant samples are 
enriched for hydroxymethylcytosine in TET2-wildtype samples.  
Comparison of intron-exon WGBS results between TET2-wildtype and TET2-mutant 
groups, where darker blue indicates increased density (a), and WGBS intron-exon 
methylation in TET2-wildtype and TET2-mutant groups as a function of density (b). hmC 
reads by RRHS in TET2-wildtype TF1 cells were compared to hypermethylated intron-
exon regions (“DMR tiles”) and all intron exon regions (“All Tiles”) (c; two sample t-test, 
*** indicates p ≤ 0.0001). WGBS methylation data and RRHS hmC data (in TET2-
wildtype) are shown for selected regions (d-g).   
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 To investigate changes in methylation seen with loss of TET2 in MDS patient 
samples, we generated two clonal TET2-null TF1 cell lines with targeted, homozygous 
disruption of the TET2 gene using CRISPR-Cas9 (Supplemental Figure 3.6). Both 
clones had reduced TET2 function as assessed by overall 5-hmC content (Supplemental 
Figure 3.6e). To identify specific sites of altered 5-hmC content, we performed 5-hmC 
sequencing using an 5-hmC-pulldown approach (RRHS, Zymo) on DNA from these cell 
lines and a TET2-WT TF1 cell line transduced with non-targeting gRNA. Consistent with 
an overall loss of 5-hmC in TET2-null cells, we observed a tenfold increase in unique 
sites captured coupled with an average tenfold increase in reads per region in the TET2-
WT samples compared to TET2-null samples. Interestingly, approximately half of the 
sites captured with significant coverage in the TET2-null samples mapped to the 
mitochondrial chromosome, which contains both 5-mC and 5-hmC (Bellizzi et al., 2013; 
Manev et al., 2012).  
 
To ensure that methylation changes were consistent between MDS samples and 
the TF1 lines, we validated a subset of the most differentially methylated DMRs from 
MDS samples in TF1 lines by methyl-DNA-immunoprecipitation (MeDIP) followed by 
qPCR (Supplemental Figure 3.7). To identify putative direct TET2 target sites, we then 
examined the overlap of RRHS and WGBS sequencing data. Interestingly, although a 
number of hmC reads corresponded to regions of hypermethylation, the majority of 
overlapping sites occurred in regions identified as non-differentially methylated between 
TET2-mutant and -WT samples by bisulfite sequencing (Supplemental Figure 3.8). This 
result may be an artifact of the inability to discriminate between 5-hmC and 5-mC by 
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bisulfite sequencing, which would point to the possibility that 5-hmC is a durable 
modification in vivo, or it may be the result of intact TET1 activity in these cells. We 
compared the overlap of sites with significant coverage by RRHS with all regions 
covered by WGBS and with DMRs, and saw a significant increase in 5-hmC in TET2-
WT cells in intron-exon regions hypermethylated in TET2-mutant samples (Figure 3.2c). 
 
 To investigate the link between intragenic methylation and alterations in 
transcription, we performed RNA sequencing on TET2-null and -WT TF1 cell lines. 
Whole-transcriptome analysis revealed few significant changes in gene expression 
between TET2-WT and -null cells (Supplemental Figure 3.9). We next examined 
alternative splicing events using the JuncBASE analysis pipeline (Brooks et al., 2011). 
We first examined the frequency of categories of alternative splicing events, irrespective 
of directionality, in TET2-null and -WT TF1 cells. The frequency of events in TET2-null 
cells was similar to baseline (WT vs WT) for all classes except cassette exon inclusion 
(Figure 3.3a). We examined directionality of alternative splicing events and found a 
significant changes in inclusion reads in the cassette, coordinate cassette, and mutually 
exclusive exon categories, indicating an increase in exon-skipping in TET2-null cells 
(Figure 3.3b).  
We then specifically examined the alternative splicing events in TET2 target 
regions.  We generated a test gene set using non-promoter intron-exon DMRs from 
WGBS data also enriched for hmC (≥5 reads) in TET2-wildtype cells by RRHS. A 
control gene set composed of highly methylated (normalized methylation ≥ 0.8) but non-
differentially methylated non-promoter intron-exon regions (non-DMR) was generated as 
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a comparator. We then examined splicing events (FPKM ≥ log2(-3), q ≤ 0.05) in each 
gene set, and found a positive enrichment for alternate splicing in the DMR gene set 
versus the non-DMR gene set (OR: 1.463642, p = 1.255e-05). Genes containing regions 
hypermethylated in TET2-mutant samples and hydroxymethylated in TET2-wildtype cells 
that are also involved in an exon-skipping event are shown in Figure 3c, and are enriched 
for hematopoietic regulators and tumor suppressors.  
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Figure 3.3: Increased exon skipping in TET2-mutant samples.  
Baseline alternate splicing was examined by comparing alternate splicing events in 
TET2-wildtype replicates (WT vs WT change ≥ 10%, p ≤ 0.01) (a, left), and splicing in 
TET2-mutant samples was compared to WT (MUT vs WT change ≥ 10%, p ≤ 0.01) (a, 
right). Alternate splicing events were plotted as a proportion of total. Directional changes 
in inclusion reads were quantified for each category of alternate splicing event (b). Genes 
with alternately spliced exons that are hypermethylated in TET2-mutant samples and 
hydroxymethylated in TET2-wildtype samples are listed in (c). 
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Discussion 
 
In aggregate, our data show that inactivating TET2 mutations in MDS results in a 
global increase in DNA methylation, and that hypermethylation due to loss of TET2 is 
enriched at intron-exon boundaries. Furthermore, we find that increased methylation at 
sites of alternate splicing correlates with shifts in splice variant ratios across a broad set 
of genes. These results are highly suggestive, given that DNA methylation at intron-exon 
boundaries affects mRNA splicing by altering interactions with RNA polymerase II 
binding partners (Flores et al., 2012; Gelfman et al., 2013; Shukla et al., 2011) and in 
light of the coincidence of somatic TET2 and spliceosome mutations, and the effects of 
loss of TET2/Tet2 on hematopoietic differentiation. We hypothesize that alterations in 
splice variant abundance due to aberrant methylation in TET2-mutant cells may affect 
hematopoietic differentiation—resulting in both an increase in self-renewal in the HSC 
compartment, and a monocyte-biased differentiation pattern—and promote the 
development of an MDS phenotype. These findings reveal a novel role for TET2 in both 
normal and dysregulated hematopoiesis, and highlight the need for further research on the 
function of intragenic DNA methylation. 
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Chapter 4: Results – Part 2 
_____________________________________________________________ 
TET2 Mutations Predict Response to Hypomethylating Agents in 
Myelodysplastic Syndrome Patients  
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Contributions 
 
 I developed protocols for in vivo and in vitro treatment with 5-azacitidine. In 
collaboration with others (see below), I performed all in vivo murine experiments, 
including drug treatment, competitive transplantation, peripheral blood analysis, and 
endpoint analysis. 
 All clinical study design was done by Rafael Bejar and David Steensma, and 
statistical analysis was performed by Rafael Bejar and Kristen Stevenson (DFCI 
Biostatistics Core). Clinical sample collection and data curation was done by Michal Bar-
Natan, Richard M. Stone, Guillermo Garcia-Manero, Hagop Kantarjian, and David 
Steensma. Michelle Chen, and Marie McConkey provided technical support for in vivo 
murine experiments. 
 
 
 
 
 
 
 
 
 
 
Note: The work presented in this chapter has been published (Bejar et al., 2014). 
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Summary 
 
The molecular basis of MDS is still being unraveled, and targeted therapies are 
not yet available. Use of hypomethylating agents such as azacitidine or decitabine, 
however, has long been considered effective treatment (Garcia-Manero, 2008; 
Stresemann and Lyko, 2008). Mutations in TET2 are among the most common genetic 
lesions in MDS to date, and are presumed to lead to genomic hypermethylation. For this 
reason, we hypothesized that patients with TET2 mutations might be more sensitive to 
hypomethylating agents than patients with intact TET2. 
 
 
Introduction 
 
DNA hypomethylating agents are the only class of drugs approved for the 
treatment of patients with higher risk myelodysplastic syndromes (MDS). Azacitidine 
(AZA) was approved by the FDA for MDS in 2004 and later shown to confer an overall 
survival benefit compared to supportive care in a randomized phase-III study (Fenaux et 
al., 2009). Decitabine (DEC), the deoxynucleotide analog of AZA, was approved for the 
treatment of MDS in 2006 based on its ability to improve blood counts and decrease bone 
marrow blasts proportions (Steensma et al., 2009). However, only 40-50% of patients 
treated with either AZA or DEC experience hematologic improvement with these agents, 
and complete responses occur in as few as 10-15% of treated patients (Fenaux and Adès, 
2009; Garcia-Manero, 2008). Effective methods for identifying patients who are most 
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likely to respond to treatment with a hypomethylating agent (HMA) would be of 
immediate clinical utility. Clinical features and patient characteristics may help stratify 
patients according to their response rates, but these models are not sufficiently conclusive 
to deny eligible patients a trial of AZA or DEC based on their predictions alone (Itzykson 
et al., 2011b; Zeidan et al., 2014). Better biomarkers of response to hypomethylating 
agents are needed. 
 
Since the FDA approval of AZA and DEC, our understanding of the molecular 
genetic basis for MDS has expanded dramatically. Recurrent somatic mutations have 
been identified in more than 40 genes, and many of these mutated genes have been 
associated with important clinical measures including overall survival (Bejar et al., 2011; 
Haferlach et al., 2013; Papaemanuil et al., 2013). Since mutated genes underlie the 
pathogenic mechanisms driving the initiation and progression of MDS, they may 
represent molecular biomarkers of drug sensitivity or resistance. This is exemplified by 
the observation that MDS with deletions of the long arm of chromosome 5 (del[5q]) have 
a striking sensitivity to lenalidomide, whereas MDS patients without this lesion are less 
likely to have a hematologic response, and much less likely to have a cytogenetic or 
prolonged response (List et al., 2006). No such cytogenetic correlate has been found for 
the hypomethylating agents, but single gene mutations involving the pathways targeted 
by these drugs may be better candidates. 
 
DEC and AZA (which is metabolized into DEC intracellularly), inhibit DNA 
methyltransferases and decrease the methylation of cytosine residues. Several of the most 
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frequently mutated genes in MDS encode proteins involved in the epigenetic regulation 
of gene expression such as TET2, DNMT3A, and ASXL1. DNMT3A is a de novo DNA 
methyltransferase and is a potential target of the hypomethylating agents. Somatic 
mutations of DNMT3A have been shown to decrease its activity, suggesting that 
pharmacologic targets other than DNMT3A are likely mediators of response to AZA and 
DEC (Stresemann and Lyko, 2008). Loss of function mutations in TET2 impair the 
ability of this enzyme to oxidize methylcytosine residues and are associated with altered 
DNA methylation patterns and decreased 5-hydroxymethylcytosine (5hmC) levels in 
MDS patient samples (Ko et al., 2010; Yamazaki et al., 2014). A small study of AZA-
treated MDS patients using Sanger sequencing to determine the mutation status of TET2 
found that mutations of this gene were associated with a slightly higher rate of response 
than in wild-type TET2 patients (Itzykson et al., 2011a). However, the investigators did 
not examine these samples for additional mutations that might have modified this result 
and did not use techniques sensitive enough to identify mutations in small disease 
subclones. Subclonal mutations in genes associated with an adverse prognosis, including 
ASXL1, RUNX1, and NRAS, have been shown to have clinical relevance regardless of 
their abundance within the dysplastic clone (Murphy et al., 2013; Papaemanuil et al., 
2013). These adverse mutations are often associated with disease progression and may 
mitigate the value of a sensitizing abnormality if they confer resistance to treatment. 
 
We hypothesize that mutations of individual genes may serve as biomarkers of 
response for MDS patients treated with hypomethylating agents. We utilized massively 
parallel sequencing to examine 40 recurrently mutated genes in disease samples from 213 
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MDS patients treated with AZA or DEC. We examined the association of mutational 
patterns at different mutant allele fractions with response to treatment and overall 
survival. We utilized a competitive murine bone marrow transplant model to test the 
sensitivity of Tet2-null and Tet2-WT hematopoietic cells to treatment with azacitidine.  
 
Results 
Spectrum of Mutations 
We examined tumor samples collected from 213 patients from three different sites 
prior to treatment with AZA, DEC, or DEC + another agent. There were no significant 
differences in pretreatment patient characteristics by treatment site (Table 4.1) or 
baseline characteristics as shown in Table 4.2. Frequently mutated regions of 40 genes 
previously shown to be somatically mutated in patients with MDS were subject to hybrid 
capture and massively parallel sequencing (Supplemental Table 4.1). These include the 
most frequently mutated splicing factors, kinase signaling genes, transcription factors, 
and epigenetic regulators such as TET2, DNMT3A, ASXL1, and EZH2. With this panel, 
we identified one or more mutations in 39 genes (Figure 4.1). In total, 94% of patients 
had a mutation in at least one recurrently mutated gene. The most frequently mutated 
genes were ASXL1 (46%), TET2 (27%), RUNX1 (20%), TP53 (18%), and DNMT3A 
(16%) followed by the splicing factor genes SRSF2 (16%), SF3B1 (15%), and U2AF1 
(14%).  
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Table 4.1: Patient Characteristics and Treatments Received by TET2 Mutational 
Status 
 
 N (%) TET2 wt TET2 Mut p-value† 
N 213 155 58  
Treatments Received     
     Azacitidine Alone 42 (20) 30 (19) 12 (21) 0.60 
     Decitabine Alone 144 (68) 103 (66) 41 (71)  
     Decitabine + Other 27 (13) 22 (14) 5 (9)  
Age, ≥ 70 yrs.  103 (48) 72 (46) 31 (53) 0.44 
Sex     
     Male    155 (73) 118 (76) 37 (64) 0.085 
     Female 58 (27) 37 (24) 21 (36)  
FAB      
     RA 30 (14) 19 (12) 11 (19)  0.13 
     RARS 24 (11) 15 (10) 9 (16)  
     RAEB 125 (59) 97 (63) 28 (48)  
     RAEB-t 6 (3) 4 (3) 2 (3)  
     CMML 21 (10) 13 (8) 8 (14)  
     Other 7 (3) 7 (5) 0 (0)  
IPSS     
      Low 11 (5) 5 (3) 6 (10) 0.019 
      Int-1 86 (40) 56 (36) 30 (52)  
      Int-2 76 (36) 61 (39) 15 (26)  
      High 37 (17) 31 (20) 6 (10)  
      Unknown 3 (1) 2 (1) 1 (2)  
Cytogenetics     
       Normal or –Y 
alone 
107 (50) 68 (44) 39 (67) 0.022 
       Complex 51 (24) 45 (29) 6 (10)  
       -7/7q- isolated or 
+1 
14 (7) 12 (8) 2 (3)  
       +8 isolated 11 (5) 8 (5) 3 (5)  
       20q- isolated 7 (3) 6 (4) 1 (2)  
       5q- isolated or +1 3 (1) 3 (2) 0 (0)  
       Other 13 (6) 9 (6) 4 (7)  
       Unknown 7 (3) 4 (3) 3 (5)  
†Test includes only known categories, chi-square test used for cytogenetics. 
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The frequency of mutations identified in these genes was largely similar to those 
identified in other MDS patient cohorts. Only ASXL1 mutations were more frequent 
compared with prior studies, many of which examined a greater proportion of lower risk 
patients without transfusion dependence, utilized less sensitive Sanger sequencing of 
ASXL1, excluded unannotated missense mutations, or excluded insertions in a 
homopolymeric tract near amino acid 642 (Bejar et al., 2011; Haferlach et al., 2013; 
Papaemanuil et al., 2013). Other previously observed patterns of mutations were 
identified in this cohort including the paucity of ASXL1 mutations in SF3B1 mutant 
samples, the near mutual exclusivity of splicing factor mutations, and the lower rate of 
other gene mutations in patients with TP53 mutations (Supplemental Figure 4.1) (Bejar 
et al., 2012; Yoshida et al., 2011). As expected, mutations of TET2, ASXL1, NRAS, EZH2, 
and SRSF2 were overrepresented in CMML cases, SF3B1 mutations were predominantly 
in RARS cases, and mutations of TP53, IDH1, and IDH2 were relatively 
underrepresented in RA/RARS patients (Supplemental Figure 4.1). The variant allele 
fractions (VAFs) of mutations were not uniform and varied greatly for individual genes 
(Figure 4.2). For example, splicing factor abnormalities had higher median variant allele 
fractions, while the VAFs for mutations in tyrosine kinase signaling genes were lower, 
indicative of their frequent presence in disease subclones. Mutations of all genes included 
samples with variants present only at low abundance. 
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Figure 4.2: Variant Allele Frequencies in Selected Genes.  
A) Quantitative measure of variant containing reads estimates the abundance of these 
mutations (uncorrected for allele copy number). Mutations of TET2 (green), TP53 
(orange), and splicing factor genes (red) are often present in the dominant clone while 
mutations of tyrosine kinase signaling genes (blue) are often present in smaller clones. 
Mutations of ASXL1 (yellow) are more widely distributed. B) Analysis of samples with 
both TET2 and ASXL1 mutations indicate that ASXL1 mutations are most often co-
dominant with or smaller than TET2 mutant clone 
 
A
B
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Clinical Findings, Variant Allele Fraction, and Response Rates 
 
The overall response rate of patients in the study was 47% with 31% achieving a 
CR according to IWG criteria revised in 2006 (Table 4.2). There was no significant 
difference in response by treatment regimen (p=0.96) or source of sample (p=0.36). IPSS 
risk groups and cytogenetic abnormalities were not associated with response rate. The 
only clinical feature significantly associated with response rate was FAB classification 
(p=0.008) driven largely by the high response rate of CMML patients (17/21, 81%). 
Thirty-five percent of RA/RARS patients achieved a response compared with 47% of 
RAEB patients. No differences were detected in the time to response for each mutation. 
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Table 4.2: Response vs. Pt. Characteristics and Treatment 
 
 
 Total Non-Responders N (%) 
Responders 
N (%) p-value† 
N, Total 213 113 (53) 100 (47)  
Treatment     
     Azacitidine Alone 42 (20) 22 (52) 20 (48) 0.96 
     Decitabine Alone 144 (68) 76 (53) 68 (47)  
     Decitabine + Other 27 (13) 15 (56) 12 (44)  
Sex     
      Male 155 (73) 82 (53) 73 (47) 0.99 
      Female 58 (27) 31 (53) 27 (47)  
Age     
      <70 yrs.  110 (52) 64 (58) 46 (42) 0.13 
      ≥70 yrs. 103 (48) 49 (48) 54 (52)  
FAB     
      RA 30 (14) 20 (67) 10 (33) 0.008† 
      RARS 24 (11) 15 (63) 9 (38)  
      RAEB 125 (59) 65 (52) 60 (48)  
      RAEB-t 6 (3) 4 (67) 2 (33)  
      CMML 21 (10) 4 (19) 17 (81)  
      Other 7 (3) 5 (71) 2 (29)  
IPSS Risk Group     
        Low/Int-1 97 (46) 53 (55) 44 (45) 0.78†† 
        Int-2/High  113 (53) 59 (52) 54 (48)  
        Unknown 3 (1) 1 (33) 2 (67)  
Cytogenetics     
       Normal  104 (49) 49 (47) 55 (53) 0.31 
       Complex 51 (24) 28 (55) 23 (45)  
       Other 51 (24) 31 (61) 20 (39)  
       Unknown 7 (3) 5 (71) 2 (29)  
†Test includes only known categories.  
††No difference was observed between the 4 individual IPSS categories (p=0.24). 
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In a prior study by Itzykson et al., mutations of TET2 detected by Sanger 
sequencing were found to predict a nearly two-fold greater response rate to AZA 
(Itzykson et al., 2011a). In our cohort, TET2 mutant patients showed only a trend toward 
increased response rates compared to wild-type (WT) (55% vs. 44%; OR 1.58 [0.86-2.89], 
p = 0.14) and no other mutated was gene was associated with a significantly improved 
overall response rate in univariate analyses (Table 4.3, Supplemental Table 4.2, 
Supplemental Figure 4.2). However, the VAF for mutations of TET2 and several other 
genes spanned a wide range of values including many likely to be below the detection 
limit for Sanger sequencing (Figure 4.2). We hypothesized that mutations capable of 
sensitizing cells to hypomethylating agents are more likely to be associated with a 
clinical response to treatment when they are present in a major disease clone. For 
example, even complete elimination of a clone representing less than 20% of bone 
marrow cells might not have any impact on the assessment of clinical response. Therefore, 
we repeated our analysis with mutations present at a VAF of <10% treated as if they were 
unmutated. For heterozygous mutations, this cutoff represents variants present in less 
than 20% of the sample cellularity and is at the estimated limit of sensitivity for Sanger 
sequencing. In this revised analysis considering VAF, mutations of TET2 were associated 
with a significantly higher response rate compared to WT (60% vs. 43%; OR 1.99 [1.0.5-
3.80], p = 0.036; adjusted OR 1.98 [1.02-3.85], p=0.044), and comparable to that shown 
by Itzykson et al (Table 4.3, Supplemental Table 4.2, Supplemental Figure 4.2).  
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Table 4.3: Association of gene mutations with response rate in logistic regression 
analysis  
 
 
Mutated Gene†  Unadjusted OR (95% CI) p-value 
  Adjusted†† 
OR (95% CI) p-value 
Mutations with VAF ≥ 10% 
TET2 mut vs. TET2 wt 1.99 (1.05, 3.80) 0.036 1.98 (1.02, 3.85) 0.044 
ASXL1 mut vs. ASXL1 wt 0.69 (0.40, 1.20) 0.19 0.68 (0.38, 1.19) 0.17 
TET2 mut + ASXL1 wt vs. other 3.65 (1.38, 9.67) 0.009 3.64 (1.35, 9.79) 0.011 
TET2 mut + ASXL1 wt vs. both wt 3.40 (1.24, 9.35) 0.011 3.36 (1.20, 9.38) 0.013 
TET2 wt + ASXL1 mut vs. both wt 0.77 (0.41, 1.46) 0.035 0.80 (0.39, 1.46) 0.039 
TET2 mut + ASXL1 mut vs. both wt 1.11 (0.48, 2.61) 0.62 1.07 (0.44, 2.61) 0.59 
CBL mut  vs. CBL wt 0.27 (0.06, 1.29) 0.10 0.28 (0.06, 1.40) 0.12 
Including All Mutations  
TET2 mut vs. TET2 wt 1.58 (0.86, 2.89) 0.14 1.60 (0.85, 3.02) 0.15 
ASXL1 mut  vs. ASXL1 wt 0.77 (0.45, 1.32) 0.34 0.74 (0.42, 1.30) 0.29 
TET2 mut + ASXL1 wt vs. other 2.37 (1.00, 5.58) 0.049 2.40 (0.99, 5.79) 0.051 
TET2 mut + ASXL1 wt vs. both wt 2.27 (0.91, 5.63) 0.055 2.27 (0.89, 5.79) 0.056 
TET2 wt + ASXL1 mut vs. both wt 0.86 (0.45, 1.64) 0.16 0.84 (0.43, 1.62) 0.15 
TET2 mut + ASXL1 mut vs. both wt 1.06 (0.47, 2.38) 0.67 1.04 (0.45, 2.44) 0.68 
CBL mut  vs. CBL wt 0.17 (0.04, 0.79) 0.023 0.18 (0.04, 0.82) 0.027 
†Reference group is listed second.  
††Adjusted for sex, age (<70, ≥70 yrs.), IPSS (Low/Int1 vs. Int2/High), and treatment 
(azacitadine alone vs. decitabine alone vs. decitabine ± other), none of the Hosmer 
and Lemeshow tests indicated a lack of fit for each model.  
 wt=wild-type, mut=mutant 
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When all VAFs were considered, only mutations of CBL, which were often of low 
VAF, were associated with a lower rate of response compared to WT (14% vs. 49%) in 
this analysis (OR 0.17 [0.04-0.79], p=0.023; adjusted OR 0.18 [0.04-0.82], p=0.027), but 
was not significant when low VAF mutations were considered WT (20% vs. 48%) (OR 
0.27 [0.06-1.30], p=0.10).  
 
By sequencing multiple genes, we had the opportunity to determine if mutations 
in additional genes could modulate the response rates of TET2 mutant patients. We 
focused on the subset of patients defined by their TET2 and ASXL1 mutation status (at 
any VAF) as these contained enough individuals for a meaningful statistical analysis. 
Patients with mutated TET2 an unmutated ASXL1 demonstrated an increased overall 
response rate compared to all others (65% vs. 44%; OR 2.37, [1.00-5.58], p=0.049) 
(Table 3). This effect was more pronounced when mutations were required to have a 
VAF ≥ 10% (74% vs. 44%; OR 3.65, [1.38-9.67], p = 0.009), representing over 10% of 
patients in this cohort (Table 4.3).  
 
In vivo Model of Azacitidine Response in Tet2-/- Cells 
The observed association between TET2 mutations and response to treatment 
could be mediated directly by TET2 loss-of-function or by indirect or cell extrinsic 
effects. To test whether TET2 loss-of-function can sensitize cells to hypomethylating 
agents, we performed a competitive murine bone marrow transplant experiment using 
hematopoietic cells from Tet2-null and wildtype littermate donors. As expected, equal 
numbers of CD45.2+ cells transplanted into CD45.1+ recipients resulted in greater 
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engraftment of Tet2-null cells by 2.5 weeks post-transplant, prior to treatment with 
azacitidine. There was no difference in peripheral blood counts between groups at this 
time point. Treatment with AZA (2.5 mg/kg M-F x 2 weeks) or vehicle was begun on day 
20 post-transplant and repeated starting on days 48, 76, and 104. Regardless of genotype, 
azacitidine-treated animals exhibited significant decreases in WBC levels and hematocrit 
and an initial drop in peripheral blood chimerism. For several subsequent cycles, AZA-
treated Tet2-null cells maintained a significantly decreased representation in peripheral 
blood while Tet2-wildtype cells did not (Figure 4.3). 
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Associations with Overall Survival 
Traditional prognostic models like the IPSS and Revised IPSS (IPSS-R) are based 
on patient cohorts examined only until they receive disease modifying therapies such as 
hypomethylating agents or undergo stem cell transplantation. Response to specific 
treatments could significantly alter the prognostic impact of adverse disease features or 
genetic alterations. We explored the relationship between mutation status and overall 
survival in the subset of patients with available survival data. Of these 146 patients (69%) 
in our cohort, 119 died during follow up. The median follow-up for patients remaining 
alive was 3.8 years (95% CI, 3.1-5.8). Despite its association with response, TET2 
mutation status was not associated with overall survival (p=0.56), consistent with the 
finding in Itzykson et al (Figure 4.4A). Mutations of TP53 were associated with lower 
overall survival (21% of patients; HR 2.01 [1.29-3.14], p=0.002; adjusted HR 1.91 [1.20-
3.05], p=0.007; Figure 4.4B) as were the much rarer mutations of PTPN11 (4% of 
patients, HR=3.26 [1.41-7.58], p=0.006; adjusted HR 2.47 [0.98-6.26], p=0.056; Figure 
4.4C)].  
 
Overall survival in patients with complex karyotypes was strongly associated with 
TP53 mutation status (Figure 4.4D). Patients with both a complex karyotype and a TP53 
mutation had a median survival of only 0.9 years. In contrast, patients with complex 
cytogenetics and no TP53 mutation had an overall survival of 1.3 years which was not 
different from patients with karyotypes other than complex (median 1.8 years, p=0.28). 
This indicates that the adverse prognostic value ascribed to the complex karyotype is 
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largely driven by its frequent association with TP53 mutations which could be used to 
better refine disease risk in this patient population. 
 
 
Figure 4.4: Kaplan-Meier curves for overall survival in the 146 out of 213 study 
patients with survival data. A) Survival of patients with and without TET2 mutations B) 
Survival of patients with and without TP53 mutations. C) Survival of patients with and 
without PTPN11 mutations. D) Survival of complex karyotype patients with and without 
TP53 mutations vs. patients without complex karyotypes.  
  
 
 
 
!
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Discussion 
 
In our study, the presence of TET2 mutation at greater than 10% allele burden 
predicted an increased response to hypomethylating agents, particularly in the subset that 
lacked similarly abundant mutations of ASXL1. To achieve this result, we examined 
tumor samples from 213 MDS patients collected prior to treatment with hypomethylating 
agents for mutations in 40 genes known to be recurrently mutated in MDS. The patients 
in our cohort were representative of those studied in clinical trials of AZA and DEC in 
terms of predicted disease risk and severity of cytopenias. Overall response rates were 
just under 50% and did not differ by the type of drug patients received. Using sensitive 
quantitative sequencing techniques, we were able to identify mutations in over 90% of 
patients in patterns similar to those seen in prior multigene studies of MDS. 
 
Our findings are consistent with those of Itzykson et al., who previously reported 
that 11 of 13 (85%) MDS patients with TET2 mutations detected by Sanger sequencing 
responded to treatment with AZA compared with a 52% response rate for their overall 
cohort of 86 patients. In that study, mutations in other genes were not examined, and 
small subclonal TET2 mutations likely went undetected. Our broader and more sensitive 
multigene analysis similarly identified TET2 mutations as predictive of response to 
hypomethylating agents in a larger cohort of patients. Surprisingly, consideration of 
mutations in other genes did not reveal additional predictors of favorable response and 
inclusion of low VAF mutations weakened the association between TET2 mutation status 
and response rate. However, our approach identified the 10% of patients with mutated 
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TET2 and wildtype ASXL1 as the group most likely to respond to treatment. Potential 
explanations for this finding include partial resistance to hypomethylating agents caused 
by ASXL1 mutations. In this model, the ASXL1 mutated subclone would be expected to 
grow in size during disease progression or relapse and might confer primary resistance. 
ASXL1 mutated patients with wildtype TET2 did have a lower likelihood of response, but 
this was not statistically significant (OR 0.63 [0.35-1.15], p=0.13). Alternatively, we 
observed that ASXL1 mutations were often subclonal or at a lower VAF than TET2 
mutations in co-mutated patients (Figure 4.2C). The acquisition of such secondary 
mutations (of which ASXL1 was the most frequent) could indicate more clonally 
progressive disease that might be inherently more resistant to treatment.  
 
The mechanism by which TET2 mutations might influence response to 
hypomethylating agents is not clear. Altered methylation has been observed in patients 
with TET2 mutations and in animal models of Tet2 loss. However, measurement of 
pretreatment DNA methylation by itself has not been found to be predictive of response 
to hypomethylating agents (Shen et al., 2010). In our murine bone marrow transplant 
experiment, exposure to AZA preferentially decreased the clonal advantage associated 
with loss of Tet2 function. This effect may be associated with a greater AZA sensitivity 
in more actively cycling cells since AZA results in cell division-dependent passive 
demethylation of DNA. Mice with hematopoietic Tet2 loss are known to have increased 
myeloid progenitor proliferation (Abdel-Wahab et al., 2012; Kunimoto et al., 2012; Li et 
al., 2011; Moran-Crusio et al., 2011). 
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An important finding of our study was that no pattern of mutation was strongly 
associated with a lack of response to treatment. Responses to hypomethylating agents 
were observed even in patients with mutations that confer a very poor prognosis. 
Therefore, our data indicate that mutation information alone should not be used as a basis 
for denying therapy with an HMA if treatment is indicated. Studies examining samples 
collected at multiple time points are needed to identify mutations predictive of acquired 
resistance or relapsed disease (Jadersten et al., 2009; Walter et al., 2013; 2012). 
 
The association between molecular or clinical biomarkers and HMA response may be 
confounded by the by variations in enzymes responsible for the activation and 
metabolism of AZA and DEC (Mahfouz et al., 2013; Saunthararajah, 2013; Stresemann 
and Lyko, 2008; Valencia et al., 2014). Patients who demonstrate significant 
hypomethylation of blood cell DNA after treatment with AZA or DEC (indicating 
sufficient exposure to target DNA methyltransferases) may be more likely to have a 
clinically significant response (Qin et al., 2011; Shen et al., 2010). It is possible that the 
predictive value of cell intrinsic somatic mutations may be enhanced if controlled for cell 
extrinsic variables such as effective dose of HMAs received and activated in cells. 
 
Over two-thirds of our cohort had survival data collected. Mutation profiles 
capable of predicting response to hypomethylating agents were not associated with 
differences in overall survival (Figure 4.3). However, mutations in two genes that were 
not predictive of response, TP53 and the rarer PTPN11, were each associated with 
decreased overall survival. The majority of TP53 mutant patients had a complex 
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karyotype, a known adverse risk factor associated with shorter overall. More than half of 
our complex karyotype patients harbored a TP53 mutation (32/51) and these patients had 
a very short overall survival (median 0.9 years). However, complex karyotype patients 
without a detectable TP53 mutation had an overall survival that was no different from the 
group of patients with non-complex karyotypes. This indicates that the negative 
prognostic significance attributed the complex karyotype can be better explained by the 
TP53 mutation status of these patients and validates the results of recent studies in MDS 
and AML (Bally et al., 2014; Bejar et al., 2011). In addition to TP53, mutations in any of 
four additional genes, RUNX1, ASXL1, EZH2, or ETV6 were found to predict shorter 
overall survival than expected by examining clinical features alone. However, mutations 
of these four genes were not found to be prognostically adverse in this cohort of treated 
patients (Supplemental Figure 4.3). In contrast, samples for our previous study were 
collected prior to the approval of AZA and DEC and therefore came largely from 
untreated patients. Our results suggest that treatment with hypomethylating agents may 
partially abrogate the adverse prognostic impact of these lesions. If validated, our finding 
would form a justification for treating patients whose adverse prognosis is driven by 
mutations in these genes. 
 
The clinical implications of our findings are that response to hypomethylating 
therapy can be predicted in a subset of patients using molecular genetic features. A more 
robust predictor might be created by incorporating clinical findings or other biomarkers 
(Alhan et al., 2014; Itzykson et al., 2011b; Valencia et al., 2014). Indeed, the Groupe 
Français des Myélodysplasies has presented a clinically and cytogenetically based 
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prognostic model for azacitidine treated patients, although its predictive power is unclear 
(Breccia et al., 2012; Itzykson et al., 2011b; Zeidan et al., 2014). As with these clinical 
measures, no mutations identified in our study were reliably strong predictors of primary 
resistance to treatment in a large number of patients. Therefore, there is no genetic 
rationale for denying MDS patients the opportunity to be treated with AZA or DEC based 
on our findings, particularly since there are few alternative therapies approved for this 
patient population.  
 
In conclusion, means of reliably predicting response to hypomethylating agents 
would be of clinical benefit in the care of patients with MDS. Our study demonstrates 
that mutation profiles can help in this effort to some extent. Studies examining the 
mechanism by which these biomarkers might mediate sensitivity or resistance to 
treatment would be of clinical value and could lead to the discovery of additional 
therapeutic targets in MDS.  
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Chapter 5 
_____________________________________________________________ 
Discussion  
!! 67!
Summary 
 
I have shown that loss of TET2 in primary MDS samples leads to global 
hypermethylation, and that this increase in methylation is localized to intron-exon 
boundaries. I have developed a TF1 cell line system to assess changes in 
hydroxymethylation and transcription in a TET2-null setting. Using this system, I have 
shown that loss of TET2 results in a global loss of 5-hmC, and that hypermethylated 
regions in TET2-mutant samples are enriched for 5-hmC-containing regions in TET2-
wildtype cells. Loss of TET2 has little impact on global transcription, but does affect 
alternate splicing events: exon-skipping, as assessed by shifts in cassette, coordinate 
cassette, and mutually exclusive exon categories of alternate splicing events, is increased 
in TET2-null cells. Regions hypermethylated in TET2 mutant samples are enriched for 
alternate splicing events overall, suggesting that exon skipping is directly due to 
increased methylation seen in the TET2-deficient setting. Finally, I have shown that 
murine Tet2-null cells display increased sensitivity to treatment with 5-azacitidine, 
functionally validating our findings that MDS patients with TET2 mutations show 
improved response to treatment with hypomethylating agents. 
 
Implications and Future Directions 
 
TET proteins and Intragenic Methylation 
 DNA methylation has been best studied in the context of gene promoters, and, 
more recently, enhancers. Because of this, methylcytosine has long been thought of as a 
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repressive mark. The work I have presented in this thesis suggests that the reality of 
methylcytosine-mediated control is more complicated.  
 Loss of Tet1 in murine ES cells has a dual effect on gene expression, and Tet1 
binds to both actively transcribed and repressed promoters (Wu et al., 2011).  Several 
groups have shown that Tet1-mediated demethylation is important for the derepression of 
some genes—notably pluripotency factors such as Nanog—but may actually directly or 
indirectly repress expression of other genes (Pastor et al., 2011; Williams et al., 2011; Wu 
et al., 2011). These results indicate that TET1 function is closely linked to promoter-
focused regulation. 
Gains in methylation due to loss of TET2 in adult human hematopoietic cells, 
unexpectedly, is not localized to promoters or enhancers. My data show, rather, that 
changes in methylation in a TET2-deficient setting are found primarily in intragenic 
regions, and predominate at intron-exon boundaries. Given the effects of TET2 loss on 
hematopoietic cells, these results suggest that intragenic methylation plays an important 
functional role in self-renewal and differentiation decisions. These results also suggest 
that TET2 function in hematopoietic cells may not overlap with that of TET1 in ES cells.  
It will be important to further study the function of intragenic methylation, 
particularly at intron-exon boundaries. Several groups have described a role for intragenic 
methylation in modulating mRNA splicing, primarily by permitting or interfering with 
binding of RNA polymerase II (Pol II) interacting proteins (Flores et al., 2012; Gelfman 
et al., 2013; Maunakea et al., 2013; Shukla et al., 2011). In this context, DNA 
methylation has universally been shown to affect exon inclusion or exclusion wholesale, 
rather than altering choice of splice sites. Interestingly, reports are conflicted as to 
!! 69!
whether increased methylation of a given exon promotes its inclusion or exclusion, which 
likely reflects some degree of tissue- or cell-type-specificity in the expression of Pol II 
interacting proteins.  
Targeted studies of methylated DNA in the context of transcription-translation are 
technically challenging, and previous work has focused on association studies (Flores et 
al., 2012; Gelfman et al., 2013), experiments on known Pol II-interacting proteins 
(Shukla et al., 2011), or genome-wide manipulations of 5-mC content through DNMT1 
depletion or treatment with HMAs (Maunakea et al., 2013). These last treatments are 
blunt tools, however, and may have indirect effects on transcription or translation more 
broadly. One possible approach to studying the effects of methylation of a single exon on 
its inclusion in mature mRNA and protein would be to use a minigene system for 
coupling transcription, splicing, and translation (Cooper, 2005; Rothrock et al., 2003; 
Singh and Cooper, 2006).  
A genomic region of interest, including three exons as well as their intervening 
introns, would need to be cloned behind a strong promoter in either a plasmid or as linear 
DNA. Appropriate restriction enzyme sites would need to be identified surrounding the 
middle exon, and this middle fragment could be PCR amplified using a custom dNTP 
mix containing 5-mC rather than C. This would result in a fully-methylated middle exon, 
which could be ligated back into its original genomic context. The resulting plasmid or 
linear DNA could be incubated directly with cellular extract from the cell type of interest 
(ideally from both TET2-deficient and TET2-wildtype cells), and in vitro transcription of 
the minigene measured by RT-PCR using plasmid-specific primers.  
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This approach would obviously be heavily dependent on choice of promoter as 
well as choice of genomic region—intron size would likely be a major technical 
consideration—and is not amenable to high-throughput studies. A minigene is inherently 
artificial, but this approach would demonstrate a direct link between methylation and 
splicing. This approach also has the added benefits of biological relevance and flexibility 
as to the available pool of possible Pol II interacting proteins, which can be varied 
according to choice of cellular extract. 
Finally, it would be interesting to interrogate the pool of Pol II binding proteins 
present in hematopoietic cells, and how those interactions are affected by loss of TET2 
and corresponding gains in methylation in a cell-specific context. An initial approach 
could involve immunoprecipitation of Pol II in TET2-null and TET2-wildtype 
hematopoietic cells, followed by immunoblotting for known Pol II interacting proteins. 
This approach would be unable to identify novel Pol II interacting proteins, however.  
An unbiased approach to identify differential protein binding in the context of 
TET2 loss would be to use SILAC followed by mass spectrometry to identify DNA 
binding proteins in a region of interest (Mittler et al., 2009; van der Ploeg, 2009). 
Biotinylated DNA oligos, with sequence derived from exons known to be 
hypermethylated and skipped in the context of loss of TET2, would be used as bait. 
TET2-null and TET2-wildtype TF1 cells (or another cell type of interest) would be grown 
in both heavy and light media, and nuclear extracts from these four conditions would be 
prepared and incubated with bait, which would then be pulled down and analyzed by 
liquid chromatography MS/MS. A control bait, with altered sequence, would need to be 
used to eliminate non-specific binding. Ultimately, proteins that bind to the sequence of 
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interest regardless of TET2 mutational status could be identified, but a second population 
of proteins that preferentially bind to the sequence of interest in the unmethylated (bait) 
state would be most interesting. In TET2-wildtype cells, bait sequence would compete for 
binding of these proteins with unmethylated genomic DNA, whereas in TET2-mutant 
cells these proteins would be unable to bind genomic DNA due to methylation status, and 
should be enriched for after pulldown. The limiting factor to this approach, aside from 
cost, would be the bait sequence—sequences of interest would need to be carefully 
designed, and this approach probably does not lend itself to a high-throughput screen.  
The interactions of any of proteins identified using this approach with the 
sequence of interest, as well as potentially with Pol II, would need to be validated using 
standard immunoprecipitation methods. Finally, to assess the role of protein-DNA 
binding on exon skipping, it would be interesting to disrupt the binding of candidate 
proteins (preferably by inducing targeted mutations in DNA-binding domains, though 
depletion of candidate proteins by shRNA or genetic deletion are alternate approaches) to 
DNA in a TET2-wildtype context.  
 
Functional Significance of Hydroxymethylcytosine 
 DNA methylation increases in a site-specific manner with loss of TET2, and we 
also see a concomitant loss of 5-hmC. As discussed previously, 5-hmC may be a transient 
intermediary in the demethylation process, but it also may be a functional mark in its own 
right. Although methylcytosine content can vary depending on tissue type (Ehrlich et al., 
1982), hydroxymethylcytosine can be found at much more variable frequencies in 
different tissues (Globisch et al., 2010; Kinney et al., 2011; Nestor et al., 2012; Song et 
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al., 2011). This may point to higher turnover of mC, indicating a greater need for active 
demethylation in certain tissue types, but it could also indicate that 5-hmC is functionally 
important in some tissues.  
Work by several groups has shown that some MBD proteins can also bind 5-hmC, 
and a recent screen identified several proteins that preferentially bind to 
hydroxymethylated DNA (Iurlaro et al., 2013; Pastor et al., 2013). Furthermore, some 
MBD proteins cannot bind to 5-hmC, suggesting that 5-hmC might be used to fine-tune 
protein-DNA interactions (Pastor et al., 2013). Further work will be needed to dissect the 
functional significance of the interactions of these proteins with modified cytosine. Tet1 
and 5-hmC are both enriched for at poised, or bivalent (marked by both activating 
H3K4Me3 and repressive H3K27Me3), promoters in ES cells, suggesting that 5-hmC 
may play a role in regulating stem cell maintenance and/or differentiation decisions 
(Pastor et al., 2011). The significance of intragenic 5-hmC has not been explored, 
although several groups have shown that 5-hmC is enriched for in gene bodies (Song et 
al., 2011; Tsagaratou et al., 2014).  
 Hydroxymethylcytosine is a rare base, comprising approximately 0.1% of total 
cytosine in most tissues. The most tractable system for studying 5-hmC is probably the 
brain, where 5-hmC is most abundant and makes up 0.3-0.6% of total cytosine (Globisch 
et al., 2010; Kriaucionis and Heintz, 2009). There may be tissue-specific differences in 5-
hmC-binding proteins, and the activity of TET proteins may vary depending on tissue 
type, so any interactions found in this system would need to be verified in others. Several 
approaches mentioned above could be used to study protein-hmC interactions, including 
an examination of interactions between known 5-hmC-binding proteins with Pol II in the 
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context of wildtype versus mutant TET, an unbiased proteomics-based approach to 
identifying novel 5-hmC interacting proteins, and minigene approaches to assess effects 
of 5-hmC on cotranscriptional splicing. 
 
Other TET functions 
 The focus of my thesis has been on the role of TET2 as a methylcytosine 
dioxygenase, and the effects of its loss on DNA methylation and hydroxymethylation. 
Recent work has shown that TET family proteins can interact with OGT and the 
SET1/COMPASS histone methyltransferase complex (Deplus et al., 2013; Vella et al., 
2013). The possibility exists that the loss of this interaction, in addition to loss of 
methylcytosine dioxygenase activity in hematopoietic cells, may explain some of the 
phenotypes seen with loss of TET2. It will be important to investigate how these 
interactions affect hematopoietic specification and differentiation.  
TET colocalization with OGT has been described in murine ES cells and HEK293 
cells as occurring primarily at promoters, however (Deplus et al., 2013). This interaction 
may therefore be functionally distinct from interactions resulting in intragenic 
hydroxymethylation. It would be interesting to examine intragenic 
methylation/hydroxymethylation, as well as TET2 localization, in the context of OGT 
depletion in hematopoietic cells. For initial in vitro studies, primary mouse or human 
cells would be most relevant, but a hematopoietic lineage cell line with wildtype TET2, 
such as the TF1 cell line, might also be a tractable experimental system. In vivo studies 
could be performed in the conditional OgtF mouse crossed to a line expressing 
hematopoietic lineage-specific Cre (e.g. Vav-Cre or Mx-Cre) (Shafi et al., 2000).  
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Alternate Splicing 
 Our data shows an increase in exon skipping events with loss of TET2, and that 
alternate splicing events are enriched for in hypermethylated regions. As discussed above, 
the importance of DNA methylation in relation to mRNA splicing will be an interesting 
area of future research. The role of alternate splicing more broadly, in MDS and other 
hematologic malignancies as well as in normal hematopoiesis, will also be important to 
study. This is especially true in light of the high frequency of mutations in splicing 
factors in myeloid malignancies.  
 Expression of alternate mRNA isoforms are known to affect both normal 
development and disease. Hematopoietic differentiation, both developmental and adult, 
can be profoundly affected by altering expression of isoforms of Runx1 (AML1), for 
example. Aberrant expression of Runx1a, which acts in a dominant negative manner to 
inhibit Runx1b function, leads to a loss of HSC self-renewal and altered differentiation, 
and promotes leukemogenesis (Liu et al., 2009). Several inherited disorders are known to 
be caused by cis-acting mutations that affect mRNA splicing, usually by altering splice 
sites, and alterations in the ratios of isoform expression can also lead to disease. In 
Parkinson’s disease, for example, mutations in the MAPT (Tau) gene promote the 
inclusion of exon 10, leading to an increase in the abundance of an isoform of Tau with 
higher microtubule binding affinity, which in turn promotes Tau aggregation. Similarly, 
mutations affecting expression of different tumor suppressor or oncogene isoforms have 
been shown to play a role in the development of various cancers. (Douglas and Wood, 
2011)  
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 Approaches to studying the role of splicing in hematopoiesis and hematologic 
malignancy are clearly needed. It will be important to consider the expression of different 
mRNA isoforms, rather than exclusively gene-level changes, when performing 
transcriptional analyses. A shift from microarray-based approaches, which are limited in 
their ability to detect known splice variants and cannot typically detect novel splice 
variants, towards unbiased sequencing of the transcriptome is an important step. A 
current lack of consensus on the most appropriate methods for analysis of alternate 
splicing events in RNA-sequencing data is another obstacle that will need to be resolved. 
As alterations in splicing are discovered in MDS and other hematologic malignancies, a 
straightforward way to explore their functional relevance will be to overexpress specific 
isoforms, but dosage effects will need to be taken into consideration. This approach lends 
itself best to analyzing the role of changes in expression of mRNA isoforms within a 
single gene or set of target genes—the phenotypic effects of widespread changes in 
transcription may prove more challenging to dissect. 
 
MDS Therapies 
 We have shown that MDS patients with TET2 mutations respond significantly 
better to treatment with HMAs than do patients without the same, or patients with more 
complicated combinations of genetic lesions. Response in these cases was measured as 
improvements in clinical parameters, but not on survival, however. Our data indicated 
that while treatment with azacitidine abrogated the repopulation advantage in Tet2-null 
cells, this effect was at the level of a progenitor or ST-HSC, and LT-HSCs remained 
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unaffected. Treatment with HMAs is therefore unlikely to eradicate disease, though it 
may help to control proliferation of more differentiated cells.  
Since TET2 mutations frequently co-occur with other somatic mutations, it would 
be interesting to test combination therapies of HMAs and other targeted therapies. Given 
the frequent coincidence of TET2 mutations and mutations in SRSF2 or ZRSR2, it would 
be especially relevant to combine HMAs and spliceosome inhibitors in the hopes of 
finding a therapeutic window for effective treatment. Human CD34+ cells from MDS or 
AML patients are more sensitive to SF3B1 inhibitors than are wildtype CD34+ cells 
(Balaian et al., 2013a; 2013b). Other drugs targeting wild-type splicing factor function 
exist (Bonnal et al., 2012), but the development of compounds targeting the neomorphic 
activies of mutant splicing factors would be incredibly useful. A chemical screen using a 
methylation-independent version of the minigene approach described above coupled with 
a luciferase or GFP reporter system could be used to sensitively detect changes in 
splicing activity in a relatively high-throughput fashion. 
Approaches to testing the efficacy of combination therapy could be done in vitro 
using patient-derived CD34+ cells, or TET2-deficient and splicing factor-neomorphic cell 
lines, but our experience has shown that the effects of azacitidine treatment are best 
modeled in vivo. Existing conditional mouse models for Tet2 and Srsf2 loss, in a 
background expressing hematopoietic lineage-specific Cre, would be an ideal model for 
preclinical studies. Competitive transplants allowing for the establishment of an 
engraftment advantage or disease phenotype represent an attractive system for assessing 
the effects of therapy on all hematopoietic compartments. 
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Concluding Remarks 
 This work has demonstrated a novel role for TET2 in specifically modulating 
intron-exon DNA methylation, and raises questions about the functional role of 
methylation in this region in hematopoiesis, myelopoiesis, and the development of 
myeloid disease. The study of DNA methylation has expanded considerably over the past 
decade, and it will be extremely interesting to see how the field resolves the challenges of 
integrating methylation and splicing data. Finally, while the treatment options available 
for MDS remain limited, our increased understanding of the molecular basis of the 
disease should allow for increased tailoring of treatment to individual patients, as well as 
combination therapy to more effectively target the MDS clone. 
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Supplemental Table 3.1: Somatic mutations in individual MDS samples. 
 
Supp. Table 1
TET2 mutation Other known somatic mutations
(c.3594+5G>A)
(c.3955-2A>G) SF3B1 p.K666T
p.C1135Y SRSF2 p.P95L
p.C1193W
p.E1082AfsX21 p.N275IfsX18 SF3B1 p.E622D
p.E1165K p.P761LfsX52 SF3B1 p.H662Y
p.E798* EZH2 p.D233G, SF3B1 p.K700E
p.G1861V SRSF2 p.P95_R102del
p.L1790TfsX32 TP53 p.Q136*
p.N374KfsX3 SRSF2 p.P95H
p.Q243* p.N482IfsX4 SF3B1 p.K700E
p.Q599* p.Y1589* SF3B1 p.H662Y
p.Q745*
p.S1583* p.A1768V p.R1176G
TET2 p.L920FfsX4 DNMT3a pR736H
TET2 p.N275IfsX18 p.P1594QfsX16 DNMT3a p.R882H
TET2_C1135Y
TET2_E184AfsX7 SRSF2 P95L
TET2_E852* SF3B1 p.K700E
TET2_K1339*
TET2_P1725T JAK2-V617F, ASXL1-P920TfsX4, U2AF1 p.Q157P
TET2_Q1527* SRSF2 p.P95H
TET2_Q1537* SF3B1 K700E
TET2_Q531* DNMT3a p.W581R, SF3B1 p.PK700E
TET2_Q642* TET2_N1266S RUNX1 p.H404PfsX196 ASXL1 p.E635RfsX15 EZH2 p.R298H p.R495GfsX19
TET2_Q685*
TET2_Q884*
TET2_R1261C
TET2_R1261H NRAS-G12S NRAS-G13D 
TET2_R1465* SRSF2 P95R
TET2_R1516* TET2_T1884A ASXL1 p.Y591*
TET2_R544* TET2_M1333K ASXL1 p.E635RfsX15 EZH2 p.I131_P132delinsMT
TET2_S1583* TET2_H1817N TET2_A1768V
TET2_S643YfsX35 TET2_F1300*
SRSF2 P95R
p53 E336GfsX9
NRAS-G12S NRAS-G13D, ASXL1 p.L697RfsX14, SRSF2 P95H
ASXL1 p.S903*
ASXL1 p.E635RfsX15
JAK2-V617F, ASXL1-Y591*, DNMT3a p.W409*
 SF3B1 p.K666N, SRSF2 p.95H
DNMT3a p.G543D, SF3B1 p.K700E
SF3B1 p.N626D, SRSF2 p.P95H
DNMT3a p.R736C, SF3B1 p.K700E
DNMT3a (c.1667+1G>T), SF3B1 p.K700E
RUNX1 p.M133_A134insV EZH2 p.C457Y (c.2111-2A>T)
ASXL1 p.Q757*, DNMT3a p.R635W, SF3B1 p.R625C
SRSF2 p.P95H
TP53 p.A159P
EZH2 p.Y663H, SF3B1 p.K700E
SF3B1 p.K700E
SRSF2 p.P95H
SRSF2 p.P95_R102del
SF3B1 p.H662Y
SF3B1 p.K700E
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Supplemental Figure 3.1: Global methylation in MDS Samples. All samples (a, b) and 
high allele fraction samples (c, d). Comparison of average methylation between TET2 
mutant and TET2 wildtype groups, where darker blue indicates increased density (a, c) 
and relative methylation of each group as a function of CpG density (b, d). 
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Supplemental Table 3.2: Characteristics of high allele fraction MDS patient samples. 
Statistics: p-values calculated using two-tailed independent t-test. Unless indicated, p = 
n.s. 
 
 
 
 
 
 
TET2 WT TET2 Mutant
n = 17 17
Age (SD) 70.06 (6.58) 70.71 (8.51)
Sex
M 13 17
F 4 0 p=0.04*
FAB
RA 7 7
RARS 4 3
RAEB/RAEB-t 6 7
AML 0 0
IPSS
Low 4 5
Int1 8 8
Int2 4 4
Unknown 1 0
CBC
% Blast (SD) 5.06 (4.78) 4.24 (4.18)
Cellularity (SD) 64.38 (24.35) 66.77 (30.41)
Hgb (SD) 9.58 (1.55) 10.15 (1.46)
WBC (SD) 3.97 (2.46) 7.86 (16.76)
ANC (SD) 16.66 (25.14) 8.79 (14.56)
Lymph (SD) 36.91 (24.90) 43.27 (19.98)
Mono (SD) 11.08 (9.45) 8.88 (6.05)
Platelets (SD) 169.24 (164.57) 125.59 (129.08)
Other Mutations
RUNX1 1 1
TP53 1 1
JAK2 1 1
NRAS 0 0
ASXL1 4 4
EZH2 2 3
DNMT3A 3 1
SF3B1 5 3
SRSF2 3 5
U2AF1 0 1
Supplemental Table 2
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Supplemental Figure 3.2: TET2 VAF in TET2-mutant MDS samples. Variant allele 
fractions could be estimated based on MALDI-TOF mass spectrometry (Sequenom) for 
the majority of MDS samples. 
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Supplemental Table 3.3: Methylation and CpG Content for all genomic regions. 
 
 
 
 
 
 
 
 
 
Region
Hypermethylated CpGs        
(% Total Hypermethylated)
Hypomethylated CpGs               
(% Total Hypomethylated)
CpGs                     
(% Total CpGs)
Promoter 94 (5.7) 46 (15.5) 230289 (35.0)
CGI 148 (9.0) 106 (35.7) 296317 (45.0)
CGI Shores 260 (15.8) 105 (35.4) 110867 (16.8)
Non-Promoter 
Intron-Exon 
Junctions 351 (21.4) 54 (18.2) 77824 (11.8)
Enhancer 90 (5.5) 39 (13.1) 161912 (24.6)
LINE 69 (4.2) 3 (1.0) 13550 (2.1)
SINE 160 (9.7) 25 (8.4) 120436 (18.3)
LTR 107 (6.5) 8 (2.7) 19949 (3.0)
3' UTR 44 (2.7) 13 (4.4) 10066 (1.5)
5' UTR 107 (6.5) 25 (8.4) 109844 (16.7)
Introns 842 (51.2) 142 (47.8) 315697 (47.9)
Exons 269 (16.4) 106 (35.7) 146583 (22.3)
Introns              
(Junctions 
Excluded) 736 (44.8) 116 (39.1) 214834 (32.6)
Exons            
Junctions 
Excluded) 44 (2.7) 13 (4.4) 17313 (2.6)
None 319 (19.4) 39 (13.1) 60499 (9.2)
All 1644 (100) 297 (100) 658609 (100)
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Supplemental Figure 3.3: Intron-Exon and promoter methylation in TET2/Tet2 
deficient CD34+ cells and mouse LSK cells. Relative methylation is shown as a 
function of density in CD34+ cells transduced with shRNA against TET2 or control (a, b) 
and sorted murine LSK cells from pI:pC-treated mice (c, d). All mice are Mx-Cre+, 
genotypes as indicated. Regions shown are intron-exon boundaries excluding promoters 
(a), intron-exon boundaries including promoters (c), and promoters (b, d). 
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Supplemental Figure 3.4: Representative sequencing coverage (RRBS). Number of 
global reads are shown for two representative TET2-wildtype (a) and TET2-mutant (b) 
MDS samples. 
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Supplemental Table 3.4: Characteristics of MDS samples used for WGBS. 
 
 
 
TET2 WT TET2 Mutant
n = 2 2
Age (SD) 62.5 (12.02) 60 (8.49)
Sex
M 0 2
F 2 0
FAB
RA 1 1
RARS 1 1
RAEB/RAEB-t 0 0
AML 0 0
IPSS
Low 2 2
CBC
% Blast (SD) 2 (1.41) 2 (1.41)
Cellularity (SD) 70 (0) 67.5 (38.89)
HGB (SD) 8.55 (2.05) 11.1 (0.85)
WBC (SD) 8.58 (0.32) 3.49 (1.58)
ANC (SD) 5.92 (0.34) 1.35 (0.83)
Lymph (SD) 21.5 (4.95) 51.5 (2.12)
Mono (SD) 6.5 (3.54) 10 (7.07)
Platelets (SD) 246 (151.32) 216.5 (20.51)
Other Mutations
RUNX1 0 0
TP53 0 0
JAK2 0 0
NRAS 0 0
ASXL1 0 1
EZH2 0 0
DNMT3A 0 1
SF3B1 1 1
SRSF2 1 0
U2AF1 0 0
Supplemental Table 3
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Supplemental Figure 3.5: Global methylation and promoter methylation in MDS 
samples by WGBS. Comparison of methylation by RRBS (y-axis) and WGBS (x-axis in 
TET2-wildtype samples (a) and TET2-mutant samples (b). Red line indicates best-fit by 
LOESS. Global methylation (c) and promoter methylation (e) by WGBS is shown as a 
function of density (c) and global differential methylation (relative TET2-mutant 
methylation—relative TET2-wildtype methylation) is shown by frequency (d).  
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Supplemental Figure 3.6: Engineering targeted mutations in TET2 using the 
CRISPR-Cas9 system in TF1 cells. The first three exons of TET2, including the guide 
RNA target sequence (inset) in exon 3 (a). Sequencing results for two separate single-
cell-derived TF1 clones the Cas9 nuclease and gRNA targeting TET2. Clone A12 (b) 
contains a single nucleotide insertion, while clone C12 (c) contains a 5-nucleotide 
deletion. Dotblot for 5-hmC in genomic DNA of control, A12, and C12 TF1 cell clones 
(d).  
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Supplemental Figure 3.7: Validation of RRBS/WGBS in TF1 cells by Me-DIP-
PCR. A subset of highly differentially methylated regions (TET2-mutant – TET2-
wildtype) in MDS samples (a) was assessed for mC content in TF1 cells by Me-DIP-
PCR (see methods for details). mC content for each region displayed as percent of 
total normalized to input DNA (b-f). All immunoprecipitations used standard high 
salt conditions, except for RIN2, ROGDI (low salt). Error bars represent SEM; 
significance calculated by two-tailed t-test (* indicated p≤0.05).  
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Supplemental Figure 3.8: Overlap of hmC and WGBS data. Regions with good 
coverage (>5 reads) in both RRHS (y-axis) and WGBS intron-exon (x-axis) datasets were 
compared. WGBS reads were plotted by normalized differential methylation (normalized 
methylation for TET2-wildtype samples were subtracted from normalized methylation 
values in TET2-mutant samples). Panel A shows all overlapping regions, while Panel B 
focuses on highly overlapping regions. 
 
 
ï  

1
2
3
4
WGBS Difference (mXW7(7ïZW7(7
OR
J

7
(
7

:
7
K
P
&
5
HD
G
1
XP
EH
U
ï ï ï    










a b
WGBS Difference (mXW7(7ïZW7(7
OR
J

7
(
7

:
7
K
P
&
5
HD
G
1
XP
EH
U
6XSS)LJ
!! 103!
 
Supplemental Figure 3.9: Correlation analysis of RNA-Seq data. Log-transformed 
FPKM values were plotted for all well-covered (Log(FPKM)>5) reads in TET2-wildtype 
(y-axis) and TET2-mutant TF1 cell samples. Best-fit line was generated using linear 
regression, R2 = 0.97301. 
 
 
 
 
 
 
 
 
 
 
0.1
1
10
100
1000
10000
100000
0.1 1 10 100 1000 10000
Log(Average TET2-mutant FPKM)
Lo
g(
Av
er
ag
e 
TE
T2
-W
T 
FP
KM
)
!! 104!
Supplemental Table 4.1: Selected target regions included coding exons of 
recurrently mutated genes plus an additional 10 nucleotides on either side to 
encompass consensus splicing sequences. 
 
Supplemental Table 1: Selected target re ions incl ded coding exons of rec rrently mutated genes plus an 
additional 10 nucleotides on either side to encompass consensus splicing sequences. 
Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr1 43814924 43815040 MPL e10 
chr1 115251142 115251281 NRAS e5 
chr1 115252180 115252359 NRAS e4 
chr1 115256411 115256609 NRAS e3 
chr1 115258661 115258791 NRAS e2 
chr2 25457138 25457299 DNMT3A e23 
chr2 25458566 25458704 DNMT3A e22 
chr2 25459795 25459884 DNMT3A e21 
chr2 25461989 25462094 DNMT3A e20 
chr2 25463161 25463329 DNMT3A e19 
chr2 25463499 25463609 DNMT3A e18 
chr2 25464421 25464586 DNMT3A e17 
chr2 25466757 25466861 DNMT3A e16 
chr2 25467014 25467217 DNMT3A e15 
chr2 25467399 25467531 DNMT3A e14 
chr2 25468112 25468211 DNMT3A e13 
chr2 25468879 25468943 DNMT3A e12 
chr2 25469019 25469188 DNMT3A e11 
chr2 25469479 25469655 DNMT3A e10 
chr2 25469910 25470037 DNMT3A e9 
chr2 25470450 25470628 DNMT3A e8 
chr2 25470896 25471131 DNMT3A e7 
chr2 25497800 25497966 DNMT3A e6 
chr2 25498359 25498422 DNMT3A e5 
chr2 25505300 25505590 DNMT3A e4 
chr2 25522998 25523122 DNMT3A e3 
chr2 25536772 25536863 DNMT3A e2 
chr2 198257017 198257195 SF3B1 e25 
chr2 198257686 198257922 SF3B1 e24 
chr2 198260770 198261062 SF3B1 e23 
chr2 198262699 198262850 SF3B1 e22 
chr2 198263175 198263315 SF3B1 e21 
chr2 198264769 198264900 SF3B1 e20 
chr2 198264966 198265168 SF3B1 e19 
chr2 198265429 198265670 SF3B1 e18 
chr2 198266114 198266259 SF3B1 e17 
chr2 198266456 198266622 SF3B1 e16 
chr2 198266699 198266864 SF3B1 e15 
chr2 198267270 198267560 SF3B1 e14 
chr2 198267663 198267769 SF3B1 e13 
chr2 198268299 198268498 SF3B1 e12 
chr2 198269790 198269911 SF3B1 e11 
chr2 198269989 198270206 SF3B1 e10 
chr2 198272712 198272853 SF3B1 e9 
chr2 198273083 198273315 SF3B1 e8 
chr2 198274484 198274741 SF3B1 e7 
chr2 198281455 198281645 SF3B1 e6 
chr2 198283223 198283322 SF3B1 e5 
chr2 198285142 198285276 SF3B1 e4 
chr2 198285743 198285867 SF3B1 e3 
chr2 198288522 198288708 SF3B1 e2 
chr2 198299686 198299733 SF3B1 e1 
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Supplemental Table 4.1, continued 
 
Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr2 209113083 209113394 IDH1 e4 
chr3 105438881 105439104 CBLB e10 
chr3 105452843 105452994 CBLB e9 
chr3 128199852 128200171 GATA2 e6 
chr3 128200652 128200797 GATA2 e5 
chr3 128202693 128202858 GATA2 e4 
chr3 128204560 128205221 GATA2 e3 
chr3 128205636 128205884 GATA2 e2 
chr4 55593572 55593718 KIT e11 
chr4 55599226 55599368 KIT e17 
chr4 106155090 106158518 TET2 e3 
chr4 106162486 106162596 TET2 e4 
chr4 106163981 106164094 TET2 e5 
chr4 106164717 106164945 TET2 e6 
chr4 106180766 106180936 TET2 e7 
chr4 106182906 106183015 TET2 e8 
chr4 106190757 106190914 TET2 e9 
chr4 106193711 106194085 TET2 e10 
chr4 106196195 106197686 TET2 e11 
chr5 170834694 170834788 NPM1 e10 
chr5 170837521 170837579 NPM1 e11 
chr7 139044998 139045078 LUC7L2 e1 
chr7 139060798 139060912 LUC7L2 e2 
chr7 139083335 139083453 LUC7L2 e3 
chr7 139086873 139087003 LUC7L2 e4 
chr7 139090380 139090543 LUC7L2 e5 
chr7 139091910 139092106 LUC7L2 e6 
chr7 139094299 139094410 LUC7L2 e7 
chr7 139097287 139097336 LUC7L2 e8 
chr7 139102274 139102485 LUC7L2 e9 
chr7 139106899 139107096 LUC7L2 e10 
chr7 140453065 140453203 BRAF e15 
chr7 148504728 148504808 EZH2 e20 
chr7 148506153 148506257 EZH2 e19 
chr7 148506392 148506492 EZH2 e18 
chr7 148507415 148507516 EZH2 e17 
chr7 148508707 148508822 EZH2 e16 
chr7 148511041 148511239 EZH2 e15 
chr7 148511996 148512141 EZH2 e14 
chr7 148512588 148512648 EZH2 e13 
chr7 148513766 148513880 EZH2 e12 
chr7 148514304 148514493 EZH2 e11 
chr7 148514959 148515219 EZH2 e10 
chr7 148516678 148516789 EZH2 e9 
chr7 148523536 148523734 EZH2 e8 
chr7 148524246 148524368 EZH2 e7 
chr7 148525822 148525982 EZH2 e6 
chr7 148526810 148526950 EZH2 e5 
chr7 148529716 148529852 EZH2 e4 
chr7 148543552 148543700 EZH2 e3 
chr7 148544264 148544400 EZH2 e2 
chr9 5073688 5073795 JAK2 e14 
chr11 32410594 32410735 WT1 e10 
chr11 32413508 32413620 WT1 e9 
chr11 32414202 32414311 WT1 e8 
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Supplemental Table 4.1, continued 
 
Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr11 32417793 32417963 WT1 e7 
chr11 32421484 32421600 WT1 e6 
chr11 32438026 32438096 WT1 e5 
chr11 32439113 32439210 WT1 e4 
chr11 32449492 32449614 WT1 e3 
chr11 32450033 32450175 WT1 e2 
chr11 32456236 32456901 WT1 e1 
chr11 85956262 85956395 EED e1 
chr11 85961328 85961500 EED e2 
chr11 85963180 85963292 EED e3 
chr11 85966254 85966339 EED e4 
chr11 85967419 85967564 EED e5 
chr11 85968547 85968648 EED e6 
chr11 85975204 85975315 EED e7 
chr11 85977115 85977268 EED e8 
chr11 85979488 85979613 EED e9 
chr11 85988012 85988190 EED e10 
chr11 85988950 85989043 EED e11 
chr11 85989431 85989577 EED e12 
chr11 119148866 119149017 CBL e8 
chr11 119149210 119149433 CBL e9 
chr12 11803052 11803104 ETV6 e1 
chr12 11905374 11905523 ETV6 e2 
chr12 11992064 11992248 ETV6 e3 
chr12 12006351 12006505 ETV6 e4 
chr12 12022348 12022913 ETV6 e5 
chr12 12037369 12037531 ETV6 e6 
chr12 12038850 12038970 ETV6 e7 
chr12 12043865 12043990 ETV6 e8 
chr12 25368365 25368504 KRAS e5 
chr12 25378538 25378717 KRAS e4 
chr12 25380158 25380356 KRAS e3 
chr12 25398198 25398328 KRAS e2 
chr12 50024381 50024418 PRPF40B e1 
chr12 50025174 50025337 PRPF40B e2 
chr12 50025633 50025718 PRPF40B e3 
chr12 50026369 50026416 PRPF40B e4 
chr12 50026628 50026673 PRPF40B e5 
chr12 50026787 50026917 PRPF40B e6 
chr12 50027200 50027340 PRPF40B e7 
chr12 50027410 50027454 PRPF40B e8 
chr12 50027659 50027885 PRPF40B e9 
chr12 50028105 50028248 PRPF40B e10 
chr12 50028311 50028395 PRPF40B e11 
chr12 50028872 50029056 PRPF40B e12 
chr12 50029138 50029266 PRPF40B e13 
chr12 50029616 50029786 PRPF40B e14 
chr12 50030489 50030642 PRPF40B e15 
chr12 50031243 50031377 PRPF40B e16 
chr12 50031506 50031617 PRPF40B e17 
chr12 50035681 50035817 PRPF40B e18 
chr12 50036008 50036165 PRPF40B e19 
chr12 50036353 50036468 PRPF40B e20 
chr12 50036700 50036809 PRPF40B e21 
chr12 50036996 50037190 PRPF40B e22 
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Supplemental Table 4.1, continued 
 
Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr12 50037464 50037545 PRPF40B e23 
chr12 50037634 50037797 PRPF40B e24 
chr12 50037873 50037985 PRPF40B e25 
chr12 112856906 112856939 PTPN11 e1 
chr12 112884070 112884212 PTPN11 e2 
chr12 112888112 112888326 PTPN11 e3 
chr12 112890989 112891201 PTPN11 e4 
chr12 112892358 112892494 PTPN11 e5 
chr12 112893744 112893877 PTPN11 e6 
chr12 112910738 112910854 PTPN11 e7 
chr12 112915445 112915544 PTPN11 e8 
chr12 112915651 112915829 PTPN11 e9 
chr12 112919868 112920019 PTPN11 e10 
chr12 112924269 112924443 PTPN11 e11 
chr12 112926237 112926324 PTPN11 e12 
chr12 112926818 112926989 PTPN11 e13 
chr12 112939938 112940070 PTPN11 e14 
chr12 112942489 112942578 PTPN11 e15 
chr13 28592594 28592736 FLT3 e20 
chr13 28608014 28608138 FLT3 e15 
chr13 28608209 28608361 FLT3 e14 
chr15 90631809 90631989 IDH2 e4 
chr17 1554086 1554260 PRPF8 e43 
chr17 1554392 1554614 PRPF8 e42 
chr17 1554698 1554857 PRPF8 e41 
chr17 1554932 1555092 PRPF8 e40 
chr17 1556826 1556987 PRPF8 e39 
chr17 1557061 1557320 PRPF8 e38 
chr17 1558634 1558847 PRPF8 e37 
chr17 1559676 1559869 PRPF8 e36 
chr17 1559932 1560065 PRPF8 e35 
chr17 1561537 1561685 PRPF8 e34 
chr17 1561810 1562067 PRPF8 e33 
chr17 1562641 1562852 PRPF8 e32 
chr17 1563125 1563305 PRPF8 e31 
chr17 1563716 1563882 PRPF8 e30 
chr17 1563982 1564131 PRPF8 e29 
chr17 1564277 1564466 PRPF8 e28 
chr17 1564555 1564710 PRPF8 e27 
chr17 1564895 1565094 PRPF8 e26 
chr17 1565190 1565457 PRPF8 e25 
chr17 1576365 1576501 PRPF8 e24 
chr17 1576641 1576871 PRPF8 e23 
chr17 1577030 1577196 PRPF8 e22 
chr17 1577726 1577984 PRPF8 e21 
chr17 1578436 1578643 PRPF8 e20 
chr17 1578904 1579116 PRPF8 e19 
chr17 1579212 1579358 PRPF8 e18 
chr17 1579491 1579674 PRPF8 e17 
chr17 1579789 1580015 PRPF8 e16 
chr17 1580260 1580476 PRPF8 e15 
chr17 1580849 1580998 PRPF8 e14 
chr17 1581802 1581956 PRPF8 e13 
chr17 1582046 1582185 PRPF8 e12 
chr17 1582301 1582510 PRPF8 e11 
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Supplemental Table 4.1, continued 
 
Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr17 1582575 1582714 PRPF8 e10 
chr17 1582893 1583103 PRPF8 e9 
chr17 1584010 1584135 PRPF8 e8 
chr17 1584213 1584358 PRPF8 e7 
chr17 1584762 1584994 PRPF8 e6 
chr17 1585104 1585342 PRPF8 e5 
chr17 1585413 1585597 PRPF8 e4 
chr17 1586817 1587005 PRPF8 e3 
chr17 1587756 1587875 PRPF8 e2 
chr17 7572917 7573018 TP53 e11 
chr17 7573917 7574043 TP53 e10 
chr17 7576843 7576936 TP53 e9 
chr17 7577009 7577165 TP53 e8 
chr17 7577489 7577618 TP53 e7 
chr17 7578167 7578299 TP53 e6 
chr17 7578361 7578564 TP53 e5 
chr17 7579302 7579600 TP53 e4 
chr17 7579690 7579731 TP53 e3 
chr17 7579829 7579922 TP53 e2 
chr17 7748863 7749019 KDM6B e4 
chr17 7749180 7749298 KDM6B e5 
chr17 7749386 7749625 KDM6B e6 
chr17 7749708 7749820 KDM6B e7 
chr17 7749887 7750068 KDM6B e8 
chr17 7750127 7750344 KDM6B e9 
chr17 7750413 7750780 KDM6B e10 
chr17 7750854 7753056 KDM6B e11 
chr17 7753129 7753275 KDM6B e12 
chr17 7753380 7753505 KDM6B e13 
chr17 7754329 7754554 KDM6B e14 
chr17 7754638 7754722 KDM6B e15 
chr17 7754786 7754877 KDM6B e16 
chr17 7754956 7755124 KDM6B e17 
chr17 7755259 7755393 KDM6B e18 
chr17 7755457 7755664 KDM6B e19 
chr17 7755803 7755964 KDM6B e20 
chr17 7756308 7756454 KDM6B e21 
chr17 7756518 7756849 KDM6B e22 
chr17 29422318 29422397 NF1 e1 
chr17 29482991 29483154 NF1 e2 
chr17 29486018 29486121 NF1 e3 
chr17 29490194 29490404 NF1 e4 
chr17 29496899 29497025 NF1 e5 
chr17 29508430 29508517 NF1 e6 
chr17 29508718 29508813 NF1 e7 
chr17 29509516 29509693 NF1 e8 
chr17 29527430 29527623 NF1 e9 
chr17 29528045 29528187 NF1 e10 
chr17 29528419 29528513 NF1 e11 
chr17 29533248 29533399 NF1 e12 
chr17 29541459 29541613 NF1 e13 
chr17 29546013 29546146 NF1 e14 
chr17 29548858 29548957 NF1 e15 
chr17 29550452 29550595 NF1 e16 
chr17 29552103 29552278 NF1 e17 
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Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr17 29553443 29553712 NF1 e18 
chr17 29554226 29554319 NF1 e19 
chr17 29554531 29554634 NF1 e20 
chr17 29556033 29556493 NF1 e21 
chr17 29556843 29557002 NF1 e22 
chr17 29557268 29557410 NF1 e23 
chr17 29557850 29557953 NF1 e24 
chr17 29559081 29559217 NF1 e25 
chr17 29559708 29559909 NF1 e26 
chr17 29560010 29560241 NF1 e27 
chr17 29562619 29562800 NF1 e28 
chr17 29562926 29563049 NF1 e29 
chr17 29575992 29576147 NF1 e30 
chr17 29579946 29580028 NF1 e31 
chr17 29585352 29585530 NF1 e32 
chr17 29586040 29586157 NF1 e33 
chr17 29587377 29587543 NF1 e34 
chr17 29588719 29588885 NF1 e35 
chr17 29592237 29592367 NF1 e36 
chr17 29652828 29653280 NF1 e37 
chr17 29654507 29654867 NF1 e38 
chr17 29657304 29657526 NF1 e39 
chr17 29661846 29662059 NF1 e40 
chr17 29663341 29663501 NF1 e41 
chr17 29663643 29663942 NF1 e42 
chr17 29664376 29664610 NF1 e43 
chr17 29664827 29664908 NF1 e44 
chr17 29665033 29665167 NF1 e45 
chr17 29665712 29665833 NF1 e46 
chr17 29667513 29667673 NF1 e47 
chr17 29670017 29670163 NF1 e48 
chr17 29676128 29676279 NF1 e49 
chr17 29677191 29677346 NF1 e50 
chr17 29679265 29679442 NF1 e51 
chr17 29683468 29683610 NF1 e52 
chr17 29683968 29684118 NF1 e53 
chr17 29684277 29684397 NF1 e54 
chr17 29685488 29685650 NF1 e55 
chr17 29685977 29686043 NF1 e56 
chr17 29687495 29687731 NF1 e57 
chr17 29701021 29701183 NF1 e58 
chr17 30264256 30264549 SUZ12 e1 
chr17 30267295 30267361 SUZ12 e2 
chr17 30267431 30267515 SUZ12 e3 
chr17 30274626 30274714 SUZ12 e4 
chr17 30293156 30293225 SUZ12 e5 
chr17 30300155 30300260 SUZ12 e6 
chr17 30302491 30302742 SUZ12 e7 
chr17 30303530 30303643 SUZ12 e8 
chr17 30310008 30310133 SUZ12 e9 
chr17 30315329 30315526 SUZ12 e10 
chr17 30320251 30320362 SUZ12 e11 
chr17 30320874 30321037 SUZ12 e12 
chr17 30321573 30321750 SUZ12 e13 
chr17 30322573 30322791 SUZ12 e14 
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Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr17 30323807 30323906 SUZ12 e15 
chr17 30325667 30326032 SUZ12 e16 
chr17 74732233 74732556 SRSF2 e2 
chr17 74732871 74733252 SRSF2 e1 
chr19 33792234 33793330 CEBPA e1 
chr19 56166461 56166529 U2AF2 e1 
chr19 56170566 56170721 U2AF2 e2 
chr19 56171533 56171597 U2AF2 e3 
chr19 56171872 56171995 U2AF2 e4 
chr19 56172394 56172565 U2AF2 e5 
chr19 56173858 56173994 U2AF2 e6 
chr19 56174962 56175120 U2AF2 e7 
chr19 56179863 56179962 U2AF2 e8 
chr19 56180026 56180168 U2AF2 e9 
chr19 56180439 56180557 U2AF2 e10 
chr19 56180800 56181068 U2AF2 e11 
chr19 56185290 56185444 U2AF2 e12 
chr20 30946569 30946645 ASXL1 e1 
chr20 30954177 30954279 ASXL1 e2 
chr20 30956808 30956936 ASXL1 e4 
chr20 31015921 31016061 ASXL1 e5 
chr20 31016118 31016235 ASXL1 e6 
chr20 31017131 31017244 ASXL1 e7 
chr20 31017694 31017866 ASXL1 e8 
chr20 31019114 31019297 ASXL1 e9 
chr20 31019376 31019492 ASXL1 e10 
chr20 31020673 31020798 ASXL1 e11 
chr20 31021077 31021730 ASXL1 e12 
chr20 31022225 31025151 ASXL1 e13 
chr20 42295914 42295953 MYBL2 e1 
chr20 42302436 42302549 MYBL2 e2 
chr20 42310414 42310505 MYBL2 e3 
chr20 42311424 42311536 MYBL2 e4 
chr20 42315482 42315722 MYBL2 e5 
chr20 42320787 42320969 MYBL2 e6 
chr20 42328387 42328694 MYBL2 e7 
chr20 42331120 42331553 MYBL2 e8 
chr20 42333849 42334008 MYBL2 e9 
chr20 42338593 42338712 MYBL2 e10 
chr20 42340118 42340251 MYBL2 e11 
chr20 42341632 42341756 MYBL2 e12 
chr20 42343764 42343933 MYBL2 e13 
chr20 42344589 42344737 MYBL2 e14 
chr20 57484395 57484488 GNAS e8 
chr20 57484566 57484644 GNAS e9 
chr21 36164422 36164917 RUNX1 e8 
chr21 36171588 36171769 RUNX1 e7 
chr21 36206697 36206908 RUNX1 e6 
chr21 36231761 36231885 RUNX1 e5 
chr21 36252844 36253020 RUNX1 e4 
chr21 36259130 36259403 RUNX1 e3 
chr21 36265212 36265270 RUNX1 e2 
chr21 36421129 36421206 RUNX1 e1 
chr21 44513202 44513369 U2AF1 e8 
chr21 44514571 44514683 U2AF1 e7 
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Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chr21 44514755 44514908 U2AF1 e6 
chr21 44515538 44515656 U2AF1 e5 
chr21 44515794 44515863 U2AF1 e4 
chr21 44521466 44521552 U2AF1 e3 
chr21 44524415 44524522 U2AF1 e2 
chr21 44527551 44527614 U2AF1 e1 
chr22 30730573 30730694 SF3A1 e16 
chr22 30731446 30731537 SF3A1 e15 
chr22 30731631 30731752 SF3A1 e14 
chr22 30733005 30733179 SF3A1 e13 
chr22 30733669 30733896 SF3A1 e12 
chr22 30734768 30735033 SF3A1 e11 
chr22 30735109 30735250 SF3A1 e10 
chr22 30736175 30736380 SF3A1 e9 
chr22 30736674 30736811 SF3A1 e8 
chr22 30737671 30737884 SF3A1 e7 
chr22 30738179 30738349 SF3A1 e6 
chr22 30738784 30738878 SF3A1 e5 
chr22 30740912 30741189 SF3A1 e4 
chr22 30742291 30742518 SF3A1 e3 
chr22 30748930 30749071 SF3A1 e2 
chr22 30752709 30752791 SF3A1 e1 
chrX 39910501 39911653 BCOR e15 
chrX 39913139 39913295 BCOR e14 
chrX 39913509 39913586 BCOR e13 
chrX 39914621 39914766 BCOR e12 
chrX 39916408 39916574 BCOR e11 
chrX 39921392 39921646 BCOR e10 
chrX 39921999 39922324 BCOR e9 
chrX 39922861 39923205 BCOR e8 
chrX 39923589 39923852 BCOR e7 
chrX 39930226 39930412 BCOR e6 
chrX 39930890 39930943 BCOR e5 
chrX 39931602 39934433 BCOR e4 
chrX 39935707 39935785 BCOR e3 
chrX 39937097 39937222 BCOR e2 
chrX 15808609 15808669 ZRSR2 e1 
chrX 15809047 15809146 ZRSR2 e2 
chrX 15817985 15818086 ZRSR2 e3 
chrX 15821801 15821929 ZRSR2 e4 
chrX 15822224 15822330 ZRSR2 e5 
chrX 15826346 15826404 ZRSR2 e6 
chrX 15827313 15827451 ZRSR2 e7 
chrX 15833790 15834023 ZRSR2 e8 
chrX 15836700 15836775 ZRSR2 e9 
chrX 15838320 15838449 ZRSR2 e10 
chrX 15840844 15841375 ZRSR2 e11 
chrX 76763819 76764117 ATRX e35 
chrX 76776256 76776404 ATRX e34 
chrX 76776871 76776986 ATRX e33 
chrX 76777731 76777876 ATRX e32 
chrX 76778720 76778889 ATRX e31 
chrX 76812912 76813126 ATRX e30 
chrX 76814130 76814327 ATRX e29 
chrX 76829705 76829833 ATRX e28 
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Supplemental Table 4.1, continued 
 
 
 
 
 
 
 
 
 
Chromosome Coordinate Start Coordinate End Gene Name Exon # 
chrX 76845294 76845420 ATRX e27 
chrX 76849156 76849329 ATRX e26 
chrX 76854870 76855059 ATRX e25 
chrX 76855191 76855299 ATRX e24 
chrX 76855893 76856043 ATRX e23 
chrX 76872071 76872208 ATRX e22 
chrX 76874264 76874459 ATRX e21 
chrX 76875853 76876010 ATRX e20 
chrX 76888685 76888882 ATRX e19 
chrX 76889044 76889210 ATRX e18 
chrX 76890075 76890204 ATRX e17 
chrX 76891396 76891557 ATRX e16 
chrX 76907594 76907853 ATRX e15 
chrX 76909578 76909700 ATRX e14 
chrX 76912040 76912153 ATRX e13 
chrX 76918861 76919057 ATRX e12 
chrX 76920124 76920277 ATRX e11 
chrX 76931711 76931803 ATRX e10 
chrX 76937002 76940095 ATRX e9 
chrX 76940421 76940508 ATRX e8 
chrX 76944301 76944430 ATRX e7 
chrX 76949303 76949436 ATRX e6 
chrX 76952055 76952202 ATRX e5 
chrX 76953061 76953133 ATRX e4 
chrX 76954052 76954127 ATRX e3 
chrX 76972598 76972730 ATRX e2 
chrX 77041458 77041497 ATRX e1 
chrX 133511638 133511795 PHF6 e2 
chrX 133512025 133512146 PHF6 e3 
chrX 133527521 133527674 PHF6 e4 
chrX 133527929 133527992 PHF6 e5 
chrX 133547511 133547697 PHF6 e6 
chrX 133547843 133548006 PHF6 e7 
chrX 133549036 133549160 PHF6 e8 
chrX 133551189 133551342 PHF6 e9 
chrX 133559221 133559370 PHF6 e10 
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Supplemental Table 4.2: Overall Response Rates By Mutated Gene and VAF. 
 
 
 
 
Supplemental Table 2: Overall response rates by mutated gene and VAF. 
 All Mutations DƵƚĂƚŝŽŶƐs&шϭϬй 
Gene  N Mutations ;йͿ 
WT 
ZĞƐƉŽŶƐĞ;йͿ 
Mutated 
ZĞƐƉŽŶƐĞ;йͿ 
N 
Mutations ;йͿ 
WT 
ZĞƐƉŽŶƐĞ;йͿ 
Mutated 
ZĞƐƉŽŶƐĞ;йͿ 
ASXL1 ϵϵ;ϰϲͿ ϱϳ;ϱϬͿ ϰϯ;ϰϯͿ ϵϭ;ϰϯͿ ϲϮ;ϱϭͿ ϯϴ;ϰϮͿ 
TET2 ϱϴ;ϮϳͿ ϲϴ;ϰϰͿ ϯϮ;ϱϱͿ ϱϬ;ϮϯͿ ϳϬ;ϰϯͿ ϯϬ;ϲϬͿ 
RUNX1 ϰϮ;ϮϬͿ ϳϴ;ϰϲͿ ϮϮ;ϱϮͿ ϯϴ;ϭϴͿ ϴϬ;ϰϲͿ ϮϬ;ϱϯͿ 
TP53 ϯϵ;ϭϴͿ ϴϬ;ϰϲͿ ϮϬ;ϱϭͿ ϯϱ;ϭϲͿ 84 ;ϰϳͿ ϭϲ;ϰϲͿ 
SRSF2 ϯϱ;ϭϲͿ ϴϭ;ϰϲͿ ϭϵ;ϱϰͿ ϯϰ;ϭϲͿ ϴϮ;ϰϲͿ ϭϴ;ϱϯͿ 
DNMT3A ϯϰ;ϭϲͿ ϴϱ;ϰϳͿ ϭϱ;ϰϰͿ ϯϬ;ϭϰͿ ϴϳ;ϰϴͿ ϭϯ;ϰϯͿ 
SF3B1 ϯϮ;ϭϱͿ ϴϳ;ϰϴͿ ϭϯ;ϰϭͿ ϯϭ;ϭϱͿ ϴϴ;ϰϴͿ ϭϮ;ϯϵͿ 
U2AF1 Ϯϵ;ϭϰͿ ϴϳ;ϰϳͿ ϭϯ;ϰϱͿ Ϯϳ;ϭϯͿ ϴϴ;ϰϳͿ ϭϮ;ϰϰͿ 
NRAS Ϯϰ;ϭϭͿ ϴϱ;ϰϱͿ ϭϱ;ϲϯͿ ϭϰ;ϳͿ ϵϬ;ϰϱͿ ϭϬ;ϳϭͿ 
BCOR ϮϮ;ϭϬͿ ϴϴ;ϰϲͿ ϭϮ;ϱϰͿ ϮϬ;ϵͿ ϴϵ;ϰϲͿ ϭϭ;ϱϱͿ 
NF1 Ϯϭ;ϭϬͿ ϵϯ;ϰϴͿ ϳ;ϯϯͿ ϭϲ;ϴͿ ϵϰ;ϰϴͿ ϲ;ϯϴͿ 
EZH2 Ϯϭ;ϭϬͿ ϵϬ;ϰϳͿ ϭϬ;ϰϴͿ ϮϬ;ϵͿ ϵϭ;ϰϳͿ ϵ;ϰϱͿ 
IDH2 ϭϱ;ϳͿ ϵϲ;ϰϴͿ ϰ;ϮϳͿ ϵ;ϰͿ ϵϳ;ϰϴͿ ϯ;ϯϯͿ 
KDM6B ϭϰ;ϳͿ ϵϰ;ϰϳͿ ϲ;ϰϯͿ ϭϮ;ϲͿ ϵϰ;ϰϳͿ ϲ;ϱϬͿ 
CBL ϭϰ;ϳͿ ϵϴ;ϰϵͿ Ϯ;ϭϰͿ ϭϬ;ϱͿ ϵϴ;ϰϴͿ Ϯ;ϮϬͿ 
ATRX ϭϮ;ϲͿ ϵϳ;ϰϴͿ ϯ;ϮϱͿ ϳ;ϯͿ ϵϵ;ϰϴͿ ϭ;ϭϰͿ 
PHF6 ϭϭ;ϱͿ ϵϰ;ϰϳͿ ϲ;ϱϱͿ ϴ;ϰͿ ϵϱ;ϰϲͿ ϱ;ϲϯͿ 
PRPF8 ϭϬ;ϱͿ ϵϲ;ϰϳͿ ϰ;ϰϬͿ ϳ;ϯͿ ϵϴ;ϰϴͿ Ϯ;ϮϵͿ 
PTPN11 ϭϬ;ϱͿ ϵϳ;ϰϴͿ 3 ;ϯϬͿ Ϯ;ϭͿ ϵϵ;ϰϳͿ ϭ;ϱϬͿ 
ZRSR2 ϭϬ;ϱͿ ϵϱ;ϰϳͿ ϱ;ϱϬͿ ϴ;ϰͿ ϵϲ;ϰϳͿ ϰ;ϱϬͿ 
IDH1 ϭϬ;ϱͿ ϵϳ;ϰϴͿ ϯ;ϯϬͿ ϴ;ϰͿ ϵϳ;ϰϳͿ ϯ;ϯϴͿ 
JAK2 ϭϬ;ϱͿ ϵϲ;ϰϳͿ ϰ;ϰϬͿ ϴ;ϰͿ ϵϳ;ϰϳͿ ϯ;ϯϴͿ 
KRAS ϴ;ϰͿ ϵϴ;ϰϴͿ Ϯ;ϮϱͿ ϲ;ϯͿ ϵϴ;ϰϳͿ Ϯ;ϯϯͿ 
NPM1 ϴ;ϰͿ ϵϰ;ϰϲͿ ϲ;ϳϱͿ ϳ;ϯͿ ϵϰ;ϰϲͿ ϲ;ϴϲͿ 
ETV6 ϴ;ϰͿ ϵϱ;ϰϲͿ ϱ;ϲϯͿ ϳ;ϯͿ ϵϲ;ϰϳͿ ϰ;ϱϳͿ 
WT1 ϳ;ϯͿ ϵϰ;ϰϲͿ ϲ;ϴϲͿ ϳ;ϯͿ ϵϰ;ϰϲͿ ϲ;ϴϲͿ 
U2AF2 ϳ;ϯͿ ϵϳ;ϰϳͿ ϯ;ϰϯͿ ϱ;ϮͿ ϵϴ;ϰϳͿ Ϯ;ϮͿ 
GATA2 ϲ;ϯͿ ϵϲ;ϰϲͿ ϰ;ϲϳͿ ϲ;ϯͿ ϵϲ;ϰϲͿ ϰ;ϲϳͿ 
MYBL2 ϱ;ϮͿ ϵϳ;ϰϳͿ ϯ;ϲϬͿ ϱ;ϮͿ ϵϳ;ϰϳͿ ϯ;ϲϬͿ 
SUZ12 ϱ;ϮͿ ϵϴ;ϰϳͿ Ϯ;ϰϬͿ ϱ;ϮͿ ϵϴ;ϰϳͿ Ϯ;ϰϬͿ 
CEBPA ϰ;ϮͿ ϵϵ;ϰϳͿ ϭ;ϮϱͿ Ϯ;ϭͿ ϭϬϬ;ϰϳͿ Ϭ;ϬͿ 
EED ϯ;ϭͿ ϭϬϬ;ϰϴͿ Ϭ;ϬͿ ϯ;ϭͿ ϭϬϬ;ϰϴͿ Ϭ;ϬͿ 
PRPF40B ϯ;ϭͿ ϵϵ;ϰϳͿ ϭ;ϯϯͿ Ϯ;ϭͿ ϵϵ;ϰϳͿ ϭ;ϱϬͿ 
LUC7L2 Ϯ;ϭͿ ϵϴ;ϰϲͿ Ϯ;ϭϬϬͿ Ϯ;ϭͿ ϵϴ;ϰϲͿ Ϯ;ϭϬϬͿ 
SF3A1 2 ;ϭͿ ϵϴ;ϰϲͿ Ϯ;ϭϬϬͿ Ϯ;ϭͿ ϵϴ;ϰϲͿ Ϯ;ϭϬϬͿ 
MPL Ϯ;ϭͿ ϭϬϬ;ϰϳͿ Ϭ;ϬͿ Ϭ;ϬͿ ϭϬϬ;ϰϴͿ Ϭ;ϬͿ 
CBLB Ϯ;ϭͿ ϵϴ;ϰϲͿ Ϯ;ϭϬϬͿ ϭ;фϭͿ ϵϵ;ϰϳͿ ϭ;ϭϬϬͿ 
BRAF ϭ;фϭͿ ϵϵ;ϰϳͿ ϭ;ϭϬϬͿ Ϭ;ϬͿ ϭϬϬ;ϰϴͿ Ϭ;ϬͿ 
GNAS ϭ;фϭͿ ϭϬϬ;ϰϳͿ Ϭ;ϬͿ ϭ;фϭͿ ϭϬϬ;ϰϳͿ Ϭ;ϬͿ 
KIT ϭ;фϭͿ 99 ;ϰϳͿ ϭ;ϭϬϬͿ ϭ;фϭͿ ϵϵ;ϰϳͿ ϭ;ϭϬϬͿ 
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Supplemental Figure 4.1: Patterns of mutations consistent with results from other 
published MDS cohorts.  
Each column represents a patient sample. Each colored bar indicated a mutation of the 
gene or genes described in that row to the left. A) Patients with TP53 mutations have a 
lower frequency of mutations in other genes compared to TP53 wildtype patients and are 
strongly associated with complex karyotypes (black bars shown in karyotype row). B) 
Mutations in splicing factor genes are largely mutually exclusive. (Continued next page) 
Supplemental Figure 1: Patterns of mutations consistent with results from other published MDS cohorts. Each column represents a patient sample. Each 
colored bar indicated a mutation of the gene or genes ĚĞƐĐƌŝďĞĚŝŶƚŚĂƚƌŽǁƚŽƚŚĞůĞĨƚ͘ͿWĂƚŝĞŶƚƐǁŝƚŚTP53 mutations have a lower frequency of mutations in 
other genes compared to TP53 ǁŝůĚƚǇƉĞƉĂƚŝĞŶƚƐĂŶĚĂƌĞƐƚƌŽŶŐůǇĂƐƐŽĐŝĂƚĞĚǁŝƚŚĐŽŵƉůĞǆŬĂƌǇŽƚǇƉĞƐ;ďůĂĐŬďĂƌƐƐŚŽǁŶŝŶŬĂƌǇŽƚǇƉĞƌŽǁͿ͘ͿDƵƚĂƚŝŽŶƐin 
splicing factor genes are largely mutually exclusive͘ͿWĂƚŝĞŶƚƐǁŝƚŚ^&ϯϭŵƵƚĂƚŝŽŶƐŚĂǀĞůŽǁĞƌƌĂƚĞƐŽĨĐŽŶĐƵƌƌĞŶƚ^y>ϭŵƵƚĂƚŝŽŶƐĂŶĚŚŝŐŚĞƌƌĂƚĞƐŽĨ
concurrent DNMT3A mutations.  
A. B. 
 
 
 
 
 
 
    C.  
 
 
 
 
 
 
TK Pathway refers to mutations in any of the following: NRAS, KRAS, BRAF, CBL, JAK2, PTPN11, MPL, KIT, or CBLB. 
Karyotype colors: Black – Complex, Blue – trisomy 8, Yellow – ĚĞů;ϮϬƋͿ͕tŚŝƚĞ– Normal, Red – ĚĞů;ϱƋͿ͕'ƌĞĞŶ- -ϳͬĚĞů;ϳƋͿ͕'ƌĂǇ– Other, Orange – Unknown 
  
Supplemental Figure 1 (continued): Patterns of mutations consistent with results from other published MDS cohorts. ͿDƵƚĂƚŝŽŶƉƌŽĨŝůĞŝŶDD>ƉĂƚŝĞŶƚƐ
shows higher incidence of mutations in ASXL1, TK Pathway genes, SRSF2, and EZH2 compared with non-CMML patients. ͿDƵƚĂƚŝŽŶƉƌŽĨŝůĞŝŶZZ^ƉĂƚŝĞŶƚƐ
shows high rate of SF3B1 mutations and lower rate of ASXL1, TP53, and SRSF2 mutations.  
 
D. E.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TK Pathway refers to mutations in any of the following: NRAS, KRAS, BRAF, CBL, JAK2, PTPN11, MPL, KIT, or CBLB. 
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Supplemental Figure 4.1, continued: 
C) Patients with SF3B1 mutations have lower rates of concurrent ASXL1 mutations and 
higher rates of concurrent DNMT3A mutations. D) Mutation profile in CMML patients 
shows higher incidence of mutations in ASXL1, TK Pathway genes, SRSF2, and EZH2 
compared with non-CMML patients. E) Mutation profile in RARS patients shows high 
rate of SF3B1 mutations and lower rate of ASXL1, TP53, and SRSF2 mutations.  
TK Pathway refers to mutations in any of the following: NRAS, KRAS, BRAF, CBL, 
JAK2, PTPN11, MPL, KIT, or CBLB. Karyotype colors: Black – Complex, Blue – 
trisomy 8, Yellow – del(20q), White – Normal, Red – del(5q), Green - -7/del(7q), Gray – 
Other, Orange – Unknown 
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Supplemental Figure 4.2: Univariate odds ratio of response by mutated gene 
regardless of variant allele fraction is shown with 95% confidence intervals 
indicated. 
Supplemental Figure 2: Univariate odds ratio of response by mutated gene regardless of variant allele fraction is shown 
ǁŝƚŚϵϱйĐŽŶĨŝĚĞŶĐĞŝŶƚĞƌǀĂůƐ indicated. 
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Supplemental Figure 4.3: Kaplan-Meier curves for overall survival in patients with 
and without mutations in select genes shown to have association with overall 
survival in other cohorts (continued next page). 
 
 
Supplemental Figure 3: Kaplan-Meier curives for overall survival in patients with and without mutations in select genes  
shown to have association with overall survival in other cohorts.  
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Supplemental Figure 4.3, continued 
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Supplemental Figure 4.3, continued 
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Supplemental Figure 4.3, continued 
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Supplemental Figure 4.3, continued 
 
